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A B S T R A C T
Background
Concerns exist regarding antibiotic prescribing for respiratory tract infections (RTIs) owing to adverse reactions, cost, and antibacterial
resistance. One proposed strategy to reduce antibiotic prescribing is to provide prescriptions, but to advise delay in antibiotic use with
the expectation that symptoms will resolve first. This is an update of a Cochrane Review originally published in 2007, and updated in
2010 and 2013.
Objectives
To evaluate the effects on clinical outcomes, antibiotic use, antibiotic resistance, and patient satisfaction of advising a delayed prescription
of antibiotics in respiratory tract infections.
Search methods
For this 2017 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, Issue 4,
2017), which includes the Cochrane Acute Respiratory Infection Group’s Specialised Register; Ovid MEDLINE (2013 to 25 May
2017); Ovid Embase (2013 to 2017 Week 21); EBSCO CINAHL Plus (1984 to 25 May 2017); Web of Science (2013 to 25 May
2017); WHO International Clinical Trials Registry Platform (1 September 2017); and ClinicalTrials.gov (1 September 2017).
Selection criteria
Randomised controlled trials involving participants of all ages defined as having an RTI, where delayed antibiotics were compared to
immediate antibiotics or no antibiotics. We defined a delayed antibiotic as advice to delay the filling of an antibiotic prescription by at
least 48 hours. We considered all RTIs regardless of whether antibiotics were recommended or not.
Data collection and analysis
We used standard Cochrane methodological procedures. Three review authors independently extracted and collated data. We assessed
the risk of bias of all included trials. We contacted trial authors to obtain missing information.
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Main results
For this 2017 update we added one new trial involving 405 participants with uncomplicated acute respiratory infection. Overall, this
review included 11 studies with a total of 3555 participants. These 11 studies involved acute respiratory infections including acute otitis
media (three studies), streptococcal pharyngitis (three studies), cough (two studies), sore throat (one study), common cold (one study),
and a variety of RTIs (one study). Five studies involved only children, two only adults, and four included both adults and children. Six
studies were conducted in a primary care setting, three in paediatric clinics, and two in emergency departments.
Studies were well reported, and appeared to be of moderate quality. Randomisation was not adequately described in two trials. Four
trials blinded the outcomes assessor, and three included blinding of participants and doctors. We conducted meta-analysis for antibiotic
use and patient satisfaction.
We found no differences among delayed, immediate, and no prescribed antibiotics for clinical outcomes in the three studies that recruited
participants with cough. For the outcome of fever with sore throat, three of the five studies favoured immediate antibiotics, and two
found no difference. For the outcome of pain related to sore throat, two studies favoured immediate antibiotics, and three found no
difference. One study compared delayed antibiotics with no antibiotic for sore throat, and found no difference in clinical outcomes.
Three studies included participants with acute otitis media. Of the two studies with an immediate antibiotic arm, one study found no
difference for fever, and the other study favoured immediate antibiotics for pain and malaise severity on Day 3. One study including
participants with acute otitis media compared delayed antibiotics with no antibiotics and found no difference for pain and fever on Day
3.
Two studies recruited participants with common cold. Neither study found differences for clinical outcomes between delayed and
immediate antibiotic groups. One study favoured delayed antibiotics over no antibiotics for pain, fever, and cough duration (moderate
quality evidence for all clinical outcomes - GRADE assessment).
There were either no differences for adverse effects or results favoured delayed antibiotics over immediate antibiotics (low quality evidence
- to GRADE assessment) with no significant differences in complication rates.
Delayed antibiotics resulted in a significant reduction in antibiotic use compared to immediate antibiotics prescription (odds ratio (OR)
0.04, 95% confidence interval (CI) 0.03 to 0.05). However, a delayed antibiotic was more likely to result in reported antibiotic use
than no antibiotics (OR 2.55, 95% CI 1.59 to 4.08) (moderate quality evidence - GRADE assessment).
Patient satisfaction favoured delayed over no antibiotics (OR 1.49, 95% CI 1.08 to 2.06). There was no significant difference in
patient satisfaction between delayed antibiotics and immediate antibiotics (OR 0.65, 95% CI 0.39 to 1.10) (moderate quality evidence
- GRADE assessment).
None of the included studies evaluated antibiotic resistance.
Authors’ conclusions
For many clinical outcomes, there were no differences between prescribing strategies. Symptoms for acute otitis media and sore
throat were modestly improved by immediate antibiotics compared with delayed antibiotics. There were no differences in complication
rates. Delaying prescribing did not result in significantly different levels of patient satisfaction compared with immediate provision of
antibiotics (86% versus 91%) (moderate quality evidence). However, delay was favoured over no antibiotics (87% versus 82%). Delayed
antibiotics achieved lower rates of antibiotic use compared to immediate antibiotics (31% versus 93%) (moderate quality evidence).
The strategy of no antibiotics further reduced antibiotic use compared to delaying prescription for antibiotics (14% versus 28%).
Delayed antibiotics for people with acute respiratory infection reduced antibiotic use compared to immediate antibiotics, but was not
shown to be different to no antibiotics in terms of symptom control and disease complications. Where clinicians feel it is safe not to
prescribe antibiotics immediately for people with respiratory infections, no antibiotics with advice to return if symptoms do not resolve
is likely to result in the least antibiotic use while maintaining similar patient satisfaction and clinical outcomes to delaying prescription
of antibiotics. Where clinicians are not confident in using a no antibiotic strategy, a delayed antibiotics strategy may be an acceptable
compromise in place of immediate prescribing to significantly reduce unnecessary antibiotic use for RTIs, and thereby reduce antibiotic
resistance, while maintaining patient safety and satisfaction levels.
Editorial note: As a living systematic review, this review is continually updated, incorporating relevant new evidence as it becomes
available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
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P L A I N L A N G U A G E S U M M A R Y
Delayed antibiotic prescriptions for respiratory tract infections
Review question
We investigated the effect of delaying antibiotic prescription compared to immediate prescription or no antibiotics for people with
respiratory tract infections including sore throat, middle ear infection, cough (bronchitis), and the common cold. We included all
RTIs regardless of whether antibiotics were indicated or not. We also evaluated antibiotic use, patient satisfaction, antibiotic resistance,
reconsultation rates, and use of supplemental therapies. This is an update of a review published in 2007, 2010, and 2013.
Background
Prescribing too many antibiotics increases the risk of adverse reactions and results in higher healthcare costs and increased antibacterial
resistance.
One strategy to reduce unnecessary antibiotic prescribing is to provide an antibiotic prescription, but with advice to delay filling the
prescription. The prescriber assesses that immediate antibiotics are not immediately required, expecting that symptoms will resolve
without antibiotics.
Study characteristics
Evidence is current to 25th May 2017. We included 11 trials with a total of 3555 participants evaluating prescribing strategies for
people with respiratory tract infections. Ten of these studies compared strategies of delaying antibiotics with immediate antibiotics.
Four studies compared delayed antibiotics with no antibiotics. Of the 11 studies, five included only children (1173 participants), two
included only adults (594 participants), and four included children and adults (1761 participants). The studies investigated a variety
of respiratory tract infections. One study involving 405 participants was new for this update.
Key results
There were no differences between immediate, delayed, and no antibiotics for many symptoms including fever, pain, feeling unwell,
cough, and runny nose. The only differences were small and favoured immediate antibiotics for relieving pain, fever, and runny nose
for sore throat; and pain and feeling unwell for middle ear infections. Compared to no antibiotics, delayed antibiotics led to a small
reduction in how long pain, fever, and cough persisted in people with colds. There was little difference in antibiotic adverse effects, and
no significant difference in complications.
Patient satisfaction was similar for people who trialled delayed antibiotics (86% satisfied) compared to immediate antibiotics (91%
satisfied), but was greater than no antibiotics (87% versus 82% satisfied). Antibiotic use was greatest in the immediate antibiotic group
(93%), followed by delayed antibiotics (31%), and no antibiotics (14%).
In the first month after the initial consultation, two studies indicated that participants were no more likely to come back and see the
doctor for delayed or immediate prescribing groups. Excluding the first month, one study found that participants were no more likely
to return to see the doctor in the 12 months after the delayed or immediate prescription for another respiratory infection, and another
study found that participants were more likely to come back and see the doctor in the next 12 months if they had had an immediate
prescription compared to a delayed prescription.
Two studies including children with acute otitis media reported on the use of other medicines in delayed and immediate antibiotic
groups. There was no difference in the use of ibuprofen, paracetamol, and otic drops in one study. In the other study, fewer spoons of
paracetamol were used in the immediate antibiotic group compared with the delayed antibiotic group on the second and third day after
the child’s initial presentation. No included studies evaluated herbal or other forms of complementary medicine.
No included studies evaluated antibiotic resistance.
Quality of the evidence
Overall, the quality of the evidence was moderate according to GRADE assessment.
When doctors feel it is safe not to immediately prescribe antibiotics, advising no antibiotics but to return if symptoms do not resolve,
rather than delayed antibiotics, will result in lower antibiotic use. However, patient satisfaction may be greater when a delayed prescribing
strategy is used. Using a delayed antibiotic strategy will still result in a significant reduction in antibiotic use compared to the use of
immediate antibiotics.
3Delayed antibiotic prescriptions for respiratory infections (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Editorial note: This is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review
is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic
Reviews for the current status of this review.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Delayed antibiotics compared to immediate antibiotics for respiratory infections
Patient or population: respiratory infect ions
Setting: primary care, emergency department, paediatric outpat ients
Intervention: delayed ant ibiot ics
Comparison: immediate ant ibiot ics
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with immediate an-
tibiotics
Risk with delayed antibi-
otics
Clinical outcomes
assessed with: pain,
malaise, fever
follow up: range 1 days
to 7 days
10 included studies contribut ing data to this com-
parison measured clinical outcomes. For the 4
studies including part icipants with cough or com-
mon cold there was no evidence of dif f erence
for clinical outcomes. 5 studies included clinical
outcome data for the presentat ion of sore throat,
and for most clinical outcomes we found no evi-
dence of dif f erence. 2 studies measured clinical
outcomes for part icipants with acute ot it is media
with 1 f inding no evidence of dif f erence in clini-
cal outcomes, and the other favouring immediate
ant ibiot ics for malaise and pain severity on Day
3. There were suf f icient outcome data to pool
results for some clinical outcome measures. For
part icipants with ot it is media and sore throat,
results favoured immediate ant ibiot ics over de-
layed ant ibiot ics for reducing pain and malaise
severity on Day 3. For part icipants with common
cold and ot it is media, there was no evidence of
dif f erences in the number of part icipants with
fever on Days 3 to 6
- 2419
(10 RCTs)
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Antibiot ic use: delayed
versus immediate an-
t ibiot ics
930 per 1000 348 per 1000
(286 to 401)
OR 0.04
(0.03 to 0.05)
1963
(7 RCTs)
⊕⊕⊕©
MODERATE
1
Patient sat isfact ion: de-
layed versus immediate
ant ibiot ics
909 per 1000 866 per 1000
(795 to 916)
OR 0.65
(0.39 to 1.10)
1633
(6 RCTs)
⊕⊕⊕©
MODERATE
1
Reconsultat ion rate: de-
layed versus immediate
ant ibiot ics
109 per 1000 113 per 1000
(63 to 196)
OR 1.04
(0.55 to 1.98)
379
(2 RCTs)
⊕⊕⊕©
MODERATE
1
Adverse ef fects of an-
t ibiot ics (Adverse ef -
fects)
assessed with: diar-
rhoea, vomit ing, rash
follow-up: range 1 days
to 7 days
The outcome of diarrhoea was measured by 4
studies and results favoured delayed ant ibiot ics
in 2 studies, and there was no evidence of dif f er-
ence the other 2. The outcome of vomit ing was
measured by 3 studies with no evidence of dif -
ference in 2, and results favouring immediate an-
t ibiot ics in a third. The results for rash,measured
by 2 studies, were suf f icient ly homogenous to
conduct meta-analysis, and results showed no
evidence of dif f erence
- 1303
(5 RCTs)
⊕⊕©©
LOW
12
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded 1 level because more than half of studies were not adequately blinded and did not adequately report allocat ion
concealment
2 Downgraded 1 level as results were inconsistent (I2 = 93% for vomit ing, I2 = 72% for diarrhoea, I2 = 0% for rash)6
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B A C K G R O U N D
Description of the condition
Over the past 70 years antimicrobials have transformed medicine,
greatly reducing morbidity and mortality. However, the develop-
ment of resistance to antimicrobials has increased substantially in
recent decades. Each year in the USA, at least 2 million people ac-
quire infections with antibiotic-resistant bacteria, causing approx-
imately 23,000 deaths (CDC 2017). The most significant cause
for the development of resistance is considered to be excessive and
inappropriate use of antibiotics for both humans, Goossens 2005;
Sun 2012, and animals (Kempf 2016). A number of recent system-
atic reviews suggest that antibiotics only slightly modify the course
of respiratory tract infections (RTIs) including acute otitis media
(Venekamp 2015), sore throat (Spinks 2013), and acute bronchi-
tis (Smith 2014), and have no effect on the common cold (Arroll
2013). Despite this, most antibiotics continue to be prescribed in
primary care and mainly for people with RTIs (Goossens 2005;
WHO 2014).
Description of the intervention
Strategies to reduce inappropriate antibiotic prescribing aim to re-
duce antibiotic resistance, adverse drug-related events, and health-
care costs (AHRQ 2016).
One strategy is to advise patients to delay filling prescriptions, and
to fill it only if symptoms persist or deteriorate. delayed antibiotics
have been advocated as a means of demonstrating to patients that
antibiotics are not always necessary, without making them feel
under-serviced (Arroll 2002b). Two ways of using this strategy
have been deployed: giving the patient the antibiotic prescription
(with instructions not to use unless there is deterioration), and
making the prescription available at the clinic (to be picked up in
the event of deterioration).
How the intervention might work
Delaying antibiotics may provide a feeling of safety for both pa-
tient and clinician should illness deteriorate. This intervention
provides the safety of having a prescription of antibiotics available,
yet an educational way of experiencing whether the illness resolves
spontaneously without their use.
A systematic review showed that using delayed antibiotics for peo-
ple with RTIs significantly reduced antibiotic prescribing (Arroll
2003a). The reduction ranged from a risk ratio (RR) of 0.77 (95%
confidence interval (CI) 0.73 to 0.81) to RR 0.25 (95% CI 0.19
to 0.34) (Dowell 2001; Little 1997).
Why it is important to do this review
The delayed antibiotic strategy has been advocated as a safety net
for avoiding rare but important complications of initially uncom-
plicated RTIs, and reducing antibiotic use, while enabling ade-
quate control of symptoms and providing high levels of patient
satisfaction (Little 2005b).
This review asked specifically what effect delayed antibiotics have
on clinical outcomes for people with RTIs compared to immedi-
ate antibiotic provision and no antibiotics. It also evaluated the
available data on antibiotic use, patient satisfaction, and antibiotic
resistance for three prescribing strategies (delayed antibiotics, im-
mediate antibiotics, and no antibiotics). This is a Cochrane Review
update (Spurling 2007; Spurling 2010; Spurling 2013).
While previous versions of this systematic review have not sup-
ported the strategy of delayed antibiotic prescribing over no antibi-
otics, recommendations for delay persist in international guide-
lines, and continue to be discussed in the literature (De la Poza
Abad 2016; NICE 2016).
A 2016 review that investigated strategies to improve antibiotic
prescribing for people with uncomplicated RTIs prepared for the
Agency for Healthcare Research and Quality in the USA high-
lighted the need for ongoing, systematic evaluation of these strate-
gies, and the importance of ensuring that policy and practice is in-
formed by a strong and up-to-date evidence base (AHRQ 2016).
AHRQ 2016 also highlighted the need for further research report-
ing on resistance.
Following the publication of this 2017 review update, it will be
maintained as a living systematic review. This means we will be
continually running the searches, and incorporating any newly
identified evidence (for more information about the living system-
atic review approach being piloted by Cochrane, see Appendix 1).
We believe a living systematic review approach is appropriate for
this review for the following reasons. First, the review addresses an
important topic for clinical practice; second, this review has been
identified as a priority review (Cochrane 2017); and third, we are
planning to use this living systematic review as the basis of a living
recommendation in a clinical practice guideline (Appendix 2).
O B J E C T I V E S
To evaluate the effects on clinical outcomes, antibiotic use, an-
tibiotic resistance, and patient satisfaction of advising a delayed
prescription of antibiotics in respiratory tract infections.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We included randomised controlled trials (RCTs). We included
studies reported as full text, those published as abstract only, and
unpublished data. Open randomised trials that did not include
blinding were accepted for inclusion.
Types of participants
We included adults and children diagnosed with RTIs.
Types of interventions
We included trials that investigated use of the following.
1. Delayed antibiotic use, defined as a strategy involving the
use of or advice to use antibiotics more than 48 hours after the
initial consultation.
2. Immediate antibiotic use, defined as the immediate use of a
prescription of oral antibiotics given at the initial consultation.
3. No antibiotic use, defined as no prescription of antibiotics
at the initial consultation.
Types of outcome measures
Primary outcomes
We aimed to compare delayed antibiotics with immediate antibi-
otics and delayed antibiotics withno antibiotics.
1. Clinical outcomes for sore throat, acute otitis media,
bronchitis (cough), and common cold (we included duration
and severity measures for the following symptoms: pain, malaise,
fever, cough, and rhinorrhoea).
2. Antibiotic use.
3. Patient satisfaction (measured on a four- to six-point Likert
scale; we defined satisfaction as including moderately satisfied,
very satisfied, and extremely satisfied).
4. Antibiotic resistance.
Secondary outcomes
1. Adverse effects of antibiotics.
2. Complications of disease.
3. Reconsultation.
4. Use of other therapies such as simple analgesia, e.g.
paracetamol and ibuprofen.
Search methods for identification of studies
Electronic searches
For this 2017 update we searched the Cochrane Central Register
of Controlled Trials (CENTRAL) (the Cochrane Library, Issue 4,
to 25 May, 2017), which includes the Cochrane Acute Respira-
tory Infection Group’s Specialised Register; Ovid MEDLINE In-
Process &OtherNon-Indexed Citations, OvidMEDLINEDaily,
and Ovid MEDLINE (2013 to 25 May 2017); Ovid Embase
Classic+Embase (2013 to 2017Week 21), EBSCOCINAHL Plus
(1984 to 25 May 2017); Web of Science (2013 to 25 May 2017);
WHO International Clinical Trials Registry Platform (1 Septem-
ber 2017); and ClinicalTrials.gov (1 September 2017).
In previous versions of this review, we searched MEDLINE using
keywords and MeSH terms in conjunction with the highly sen-
sitive search strategy designed by Cochrane for identifying RCTs
(Dickersin 1994).We applied no trial filters for this update. Search
strategies for all five databases can be found in Appendix 3.
We applied no language restrictions in any of the electronic
database searches, but applied date restrictions to most of the
databases, as this was an updated search.
These database searches are now being re-run using auto-alerts to
deliver the monthly yield search by email. We will review search
methods and strategies approximately yearly to ensure that they re-
flect any terminology changes in the topic area or in the databases.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references.We planned to contact experts in the
field to identify additional unpublished materials. As additional
steps to inform the living systematic review, we will contact corre-
sponding authors of ongoing studies as they are identified, and ask
them to share early or unpublished data. We will also contact the
corresponding authors of any newly included studies for advice
as to other relevant studies. We will conduct citation tracking of
included studies inWeb of Science Core Collection on an ongoing
basis, using citation alerts in Web of Science Core Collection.
Data collection and analysis
Selection of studies
Two review authors (RFo, GS) independently screened titles and
abstracts of all potential studies identified by the search for inclu-
sion in the review. We retrieved the full-text study reports, and
three review authors (CDM, LD, GS) independently screened the
full texts and identified studies for inclusion, and identified and
recorded reasons for exclusion of the ineligible studies. Any dis-
agreements were resolved through discussion or by consulting a
third review author (RFo). We identified and excluded duplicates
and collated multiple reports of the same study so that each study,
rather than each report, was the unit of interest in the review. We
recorded the selection process and completed a PRISMA flow dia-
gram and ’Characteristics of excluded studies’ table (Moher 2009).
We did not impose any language restrictions. For the monthly
searches, we will immediately screen any new citations retrieved.
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Data extraction and management
We used a data collection form for study characteristics and out-
come data that was piloted on at least one study in the review. Two
review authors (LD, CDM) extracted study characteristics from
the included studies. We extracted the following study character-
istics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (LD, CDM) independently extracted out-
come data from the included studies. We noted in the ’Character-
istics of included studies’ table if outcome data were not reported
in a usable way. Any disagreements were resolved by consensus
or by involving a third review author. One review author (RFo)
transferred data into ReviewManager 5 (RevMan 2014).We dou-
ble-checked that data were entered correctly by comparing the
data presented in the systematic review with the study reports. A
second review author (GS) spot-checked study characteristics for
accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (LD, CDM) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreements were resolved by discussion or by involving
third review author (GS). We assessed risk of bias according to the
following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear
and provided quotes from the study together with a justification
for our judgement in ’Risk of bias’ tables. We summarised the
’Risk of bias’ judgements across different studies for each of the
domains listed. We considered blinding separately for different
key outcomes where necessary. Where information on risk of bias
related to unpublished data or correspondence with a trialist, we
noted this in ’Risk of bias’ tables.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol and
reported any deviations from it in Differences between protocol
and review.
Measures of treatment effect
We entered outcome data for each study into data tables in Review
Manager 5 to calculate the treatment effects (RevMan 2014). We
used odds ratio for dichotomous outcomes and mean differences
or standardised mean differences for continuous outcomes.
We undertook meta-analyses only where this was meaningful, that
is if treatments, participants, and the underlying clinical question
were sufficiently similar for pooling to make sense.
Unit of analysis issues
The unit of analysis for each outcome was the individual study
participant.
Dealing with missing data
We planned to contact investigators or study sponsors to verify
key study characteristics and to obtain missing numerical outcome
data where possible (e.g. when we identified a study as abstract
only). Where this was not possible, and the missing data were
thought to introduce serious bias, we planned to explore the impact
of including such studies in the overall assessment of results by a
sensitivity analysis.
We also planned that if numerical outcome data were missing,
such as standard deviations or correlation coefficients, and they
were not obtainable from the study authors, we would calculate
these from other available statistics, such as P values, according to
the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the tri-
als in each analysis. If we identified substantial heterogeneity, we
planned to report this and explore for possible causes in subgroup
analysis.
Assessment of reporting biases
If we were able to pool more than 10 trials, we planned to create
and examine a funnel plot to explore possible small-study and
publication biases.
9Delayed antibiotic prescriptions for respiratory infections (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data synthesis
We have reported much of the data in this review as a narrative
synthesis describing outcome measures. As previously indicated,
we pooled results where heterogeneity was satisfactorily low. We
have conducted meta-analysis where results were sufficiently ho-
mogenous.
GRADE and ’Summary of findings’ table
We created two ’Summary of findings’ tables. One table dealt
with the comparison of delayed antibiotics versus immediate an-
tibiotics and included clinical outcomes, antibiotics use, patient
satisfaction, adverse effects of antibiotics, and reconsultation rates
(Summary of findings for the main comparison). The second ta-
ble deals with the comparison of delayed antibiotics versus no an-
tibiotics, and included clinical outcomes, antibiotics use, patient
satisfaction, and adverse effects of antibiotics. We used the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness, and publication bias) to assess the qual-
ity of a body of evidence as it relates to the studies that contribute
data to the meta-analyses for these outcomes (Atkins 2004). We
used methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), employing GRADEpro GDT soft-
ware (GRADEproGDT2014).We justified all decisions to down-
or upgrade the quality of studies using footnotes, and made com-
ments to aid the reader’s understanding of the review where nec-
essary.
Whenwe identify new evidence (studies, data or information) that
meets the review inclusion criteria, we will immediately assess risk
of bias and extract the data and incorporate it in the synthesis, as
appropriate.
Subgroup analysis and investigation of heterogeneity
We considered subgroup analyses for all outcomes and included
year of publication, clinical presentation, setting, and differences
in the intervention. We considered subgroup analyses for studies
including only children versus those including only adults where
data were available.
We described two subgroup analyses that showed differences in
outcomes. We further explored heterogeneity of antibiotic use in
delayed antibiotic arms in analyses of different delay strategy meth-
ods; we also investigated heterogeneity of patient satisfaction with
respect to blinding of outcome assessors and participants.
Sensitivity analysis
We conducted sensitivity analysis according to risk of bias.
R E S U L T S
Description of studies
Results of the search
We identified 217 records in this update. We removed 73 dupli-
cates and 97 records that were clearly not relevant based on title
alone, leaving 47 records. We assessed titles and abstracts, and re-
trieved four full-text reports. Of these, one met our inclusion crite-
ria (Figure 1). Of the remaining three, one was an excluded study
(Agnew 2013), and the other two reported longer-term outcome
data from studies that were already included in the review. Little
2006 reported long-term outcome data for the Little 2001 study,
and Moore 2009 reported longer-term outcome data for Little
2005a. We considered these reports to be part of the originally
included studies.
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Figure 1. Study flow diagram.
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Included studies
We included 11 trials involving a total of 3555 participants. Ten
trials compared immediate provision of antibiotics with delayed
antibiotics; four trials investigated sore throat (pharyngitis); two
trials considered acute otitis media (AOM); two evaluated cough
(bronchitis); one investigated common cold; and one included a
number of acute upper RTIs.
Of the 11 included trials, 1357 participants were randomised to
receive delayed antibiotics. In 10 of these trials, 1168 participants
were allocated to receive immediate antibiotics, and in four tri-
als 564 participants were allocated to receive no antibiotics. Four
studies compared the prescribing strategy of no antibiotics with de-
layed antibiotics (Chao 2008; De la Poza Abad 2016; Little 1997;
Little 2005a). These four trials investigated the presentations of
pharyngitis/sore throat (De la Poza Abad 2016; Little 1997), bron-
chitis (cough) (De la Poza Abad 2016; Little 2005a), AOM (Chao
2008), and the common cold/rhinosinusitis (De la Poza Abad
2016). Please see the Characteristics of included studies table for
details of the included trials.
Motives for studying delayed antibiotics
Early studies of sore throat were designed as efficacy trials to iden-
tify the rate of relapse of group A beta-haemolytic streptococcus
(GABHS) throat in immediate versus delayed antibiotic groups
(El-Daher 1991; Gerber 1990; Pichichero 1987). Subsequent tri-
als comparing delayed antibiotics and immediate antibiotics were
conducted with a view to evaluate the use ofdelayed antibiotics to
reduce the use of antibiotics for upper respiratory tract infections
(Arroll 2002a; De la Poza Abad 2016; Dowell 2001; Little 1997;
Little 2001; Spiro 2006).
Population
Of the 11 included studies, five included only children (Chao
2008; El-Daher 1991; Little 2001; Pichichero 1987; Spiro 2006),
two included only adults (De la Poza Abad 2016; Dowell 2001),
and four included both adults and children (Arroll 2002a; Gerber
1990; Little 1997; Little 2005a).
Setting
Of the 11 included studies, six were conducted in a primary
care setting (Arroll 2002a; De la Poza Abad 2016; Dowell 2001;
Little 1997; Little 2001; Little 2005a), three in paediatric clin-
ics (El-Daher 1991; Gerber 1990; Pichichero 1987), and two in
emergency departments (Chao 2008; Spiro 2006).
Excluded studies
Two of the studies identified in searches were extensions of pre-
viously included studies (Little 2006; Moore 2009). We excluded
one RCT because it compared usual delayed antibiotics with a
post-dated script for delayed antibiotics, and did not include either
an immediate antibiotic or a no antibiotic arm (Worrall 2010). We
excluded one new study for this update because it investigated in-
formation leaflets rather than prescribing strategies (Agnew 2013).
We excluded a total of nine studies; the other seven studies were
not RCTs (Cates 1999; De la Poza Abad 2013; Fischer 2009; Little
2014; Newson 2009; Siegel 2003; Vouloumanou 2009).
Risk of bias in included studies
Overall, we assessed the included studies as at low risk of bias.
Studiesweremost likely to be assessed as at unclear ormoderate risk
of bias for the domains of allocation concealment and blinding.
Almost all studies showed a low risk of bias for all other domains.
We assessed randomisation of studies as low risk for all of the
included studies except for two, for which the randomisation was
unclear. We assessed allocation concealment as low risk of bias
for four studies, unclear for two studies, and high risk of bias for
the five remaining studies. We assessed blinding as low risk of
bias in three studies and high risk of bias for the remaining eight
studies. For incomplete data, we assessed 10 studies as at low risk
of bias and the remaining study as at high risk of bias. We assessed
selective reporting as low risk of bias in 10 studies and unclear in
one study. We detected no other biases apart from bias associated
with funding source. Two studies were funded by pharmaceutical
companies and were assessed as at high risk of bias. We assessed
two studies for which the funding source was not described as at
unclear risk of bias. The remaining seven studies were funded by
state institutions or specialist college and were assessed as at low
risk of bias. Summaries of the risk of bias in included studies are
provided in Figure 2 and Figure 3.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Nine studies reported using random number tables or computer-
generated randomisation and were assessed as at low risk of bias.
Two studies did not describe randomisation methods and were as-
sessed as at unclear risk of bias (El-Daher 1991; Little 1997). Four
trials described adequate allocation concealment using opaque en-
velopes and were assessed as at low risk of bias (Arroll 2002a; Little
2001; Little 2005a; Spiro 2006). We assessed the remaining stud-
ies as at unclear or high risk of bias.
Blinding
Seven studies attempted to blind some or all aspects of the study,
that is participants, prescribing doctors, and outcome assessors
were blinded. We assessed three studies as at low risk of bias be-
cause they attempted to blind participants and prescribing doc-
tors without indicating if the outcome assessor was blinded (Arroll
2002a; El-Daher 1991; Pichichero 1987). In one study, partici-
pants were informed only that they would be given one of two
sets of instructions about taking antibiotics for their colds. Partic-
ipants read an information sheet and completed a consent form.
Participants were thus blinded to what the other group would take
(Arroll 2002a). Two studies used placebo (tablets) to blind partici-
pants (El-Daher 1991; Pichichero 1987). We assessed the remain-
ing eight studies as at high risk of bias in this domain. Of these
eight studies, the outcomes assessor, but not participants or pre-
scribing doctors, were blinded in four studies (Chao 2008; Dowell
2001; Little 2005a; Spiro 2006). No blinding was reported in the
other four studies (De la Poza Abad 2016; Gerber 1990; Little
1997; Little 2001).
Incomplete outcome data
We assessed one study as at high risk of bias for incomplete data
reporting because the numbers of participants enrolled did not
match the numbers of participants analysed, and this disparity was
not explained (El-Daher 1991). We assessed all other studies as
at low risk of bias, with no or very small numbers of participant
dropout.
Selective reporting
Gerber 1990 reported all clinical outcomes as one aggregated out-
come and was assessed as at unclear risk of bias. We assessed all
of the other studies as at low risk of bias because they reported on
their predetermined outcome measures.
Other potential sources of bias
Six included studies received grants from research bodies funded
by the national government where the trial was conducted (Arroll
2002a; De la Poza Abad 2016; Little 1997; Little 2001; Little
2005a; Spiro 2006). One study received funding from their rel-
evant specialist college (Dowell 2001). We assessed these seven
studies as at low risk of bias. We assessed two studies as at high
risk of bias because they received funding from pharmaceutical
companies. One study, El-Daher 1991, was funded by Biochemie
GmbH and the local university. Another study, Pichichero 1987,
was funded by both a philanthropic organisation and a pharma-
ceutical company (Eli Lilly). Two studies did not describe the
funding source (Chao 2008; Gerber 1990), and we have assessed
them as at unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Delayed
antibiotics compared to immediate antibiotics for respiratory
infections; Summary of findings 2Delayed antibiotics compared
to No antibiotics for respiratory infections
We assessed the effects of interventions using all 11 included stud-
ies. Details of the interventions are presented in Table 1 as per re-
porting recommendations published in 2017 (Hoffmann 2017).
Assessing the effectiveness of antibiotic prescribing strategies was
complicated by the heterogeneity of RTIs considered by the in-
cluded studies. This heterogeneity is important because clinical
outcomes are known to be influenced by antibiotics in different
ways depending on the type of RTI. For example, antibiotics have
been shown to reduce pain in otitis media (Venekamp 2015), but
make no difference to the symptoms of the common cold (Kenealy
2013). Additionally, authors of studies measuring the same RTI
reported clinical outcomes in a variety of ways which could not
readily be compared even after we obtained raw study data. How-
ever, we did combine the outcomes of pain (Days 3 to 6; Analysis
1.1, Analysis 1.2), malaise (Days 3 to 6; Analysis 2.1, Analysis
2.2), and fever (Days 3 to 6; Analysis 3.1, Analysis 3.2), and con-
ducted meta-analysis where this was not precluded by heterogene-
ity. Other clinical outcomes are presented in Table 2 for the com-
parison of delayed antibiotics versus immediate antibiotics, and in
Table 3 for the comparison of delayed antibiotics versus no antibi-
otics.
De la Poza Abad 2016 divided its delayed antibiotic arm into two
parts, that is a patient-led prescription strategy and a prescription
collection strategy. The patient-led prescription strategy involved
the doctor providing the patientwith a prescription that they could
fill at a pharmacy if they decided they needed to take antibiotics
based on their assessment of their symptoms. The prescription
collection strategy involved patients returning to the primary care
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health service to collect their prescription, and then filling it at a
pharmacy if they decided they required antibiotics based on their
assessment of their symptoms. The clinical outcomes of this study
are presented in Table 2 and Table 3.
Regarding the other primary outcomes, we conducted meta-anal-
yses for antibiotic use (Analysis 4.1, Analysis 4.2) and patient sat-
isfaction (Analysis 5.1, Analysis 5.2). No data were available for
antibiotic resistance.
The secondary outcomes of adverse effects of antibiotics (Analysis
6.1, Analysis 6.2, Analysis 6.3) and reconsultation (Analysis 7.1)
are presented with meta-analysis where there was sufficient homo-
geneity of included study data.
Subgroup analysis
For most subgroups, there were insufficient data to justify sub-
group analysis. However, we did analyse the two different strate-
gies of delaying antibiotics (prescription at consult with advice to
delay and return to collect prescription). Regarding study popu-
lation, two studies included only adult participants (De la Poza
Abad 2016; Dowell 2001), and neither study contributed data
that could be compared with other studies. Five studies included
only child participants (Chao 2008; El-Daher 1991; Little 2001;
Pichichero 1987; Spiro 2006); when these studies were analysed
separately there were no changes to important outcome results
except for the outcome of patient satisfaction. However, just one
study involving only childrenmeasured patient satisfaction for de-
layed antibiotics versus immediate antibiotics (Little 2001). Ad-
ditionally, just one study involving only children measured pa-
tient satisfaction for delayed antibiotics versus no antibiotics (Chao
2008). We have reported the results of the subgroup analysis for
patient satisfaction below in the appropriate section.
Primary outcomes
1. Clinical outcomes for sore throat, acute otitis media,
bronchitis, and common cold
The results for clinical outcomes were based on moderate-quality
evidence according to GRADE assessment, and are summarised
in Summary of findings for the main comparison for delayed ver-
sus immediate antibiotics, and Summary of findings 2 for delayed
versus no antibiotics.
Sore throat
Five included studies specifically examined sore throat (N = 1573)
(De la Poza Abad 2016; El-Daher 1991; Gerber 1990; Little 1997;
Pichichero 1987).
Delayed antibiotics versus immediate antibiotics
Pain was not significantly different for delayed and immediate an-
tibiotic groups in three studies (N = 939) (Gerber 1990; Little
1997; Pichichero 1987) (Table 2). In one study (El-Daher 1991),
pain was reported by a higher proportion of participants in the
delayed antibiotic group (N = 118) on Day 3 compared to the
immediate antibiotic group (N = 111) with an odds ratio (OR)
of 14.51 (95% confidence interval (CI) 7.14 to 29.50) (Table 2).
Participants in the delayed antibiotic arms (N = 91) of the study
by De la Poza Abad 2016 reported longer pain duration than par-
ticipants in the immediate antibiotic arm (N = 94) with a mean
difference (MD) of 2.01 days (95% CI 0.75 to 3.26). For partici-
pants given a script at the time of consultation this difference was
smaller with a MD of 1.30 days (95% CI -0.34 to 2.94) than for
participants required to return to pick up the script where theMD
was 3.00 days (95% CI -1.03 to 4.95) (Table 2).
Two studies measured malaise (Day 3) for delayed and immediate
antibiotic groups, with one study finding no evidence of difference
inmalaise severity onDay 3 (N=114) (Table 2) (Pichichero1987).
The other study detected amuch higher proportion of participants
with malaise on Day 3 in the delayed antibiotic group (N = 118)
compared to the immediate antibiotic group (N = 111), with an
OR of 16.49 (95% CI 5.68 to 47.83) (Table 2) (El-Daher 1991).
Five studies measured fever for delayed and immediate antibiotics
groups (N =1573) (De la Poza Abad 2016; El-Daher 1991;Gerber
1990; Little 1997; Pichichero 1987). Two studies did not report
fever in a way that could be readily compared with other studies
(Gerber 1990; Little 1997). Two studies found fever severity on
Day 3 to be higher for participants in the delayed antibiotic group
than in the immediate antibiotic group (N = 343) (El-Daher
1991; Pichichero 1987), with a pooled MD of 0.53 °C (95% CI
0.31 to 0.74) (N = 343) (Analysis 1.1). One study found that
the median number of days of fever experienced by participants
in the delayed antibiotic group (N = 235) was one day longer
than for the immediate antibiotic group (N = 247) (P = 0.04)
(Little 1997). However, in one study (N = 405) (De la Poza Abad
2016), the number of dayswith feverwas not significantly different
for participants in the delayed antibiotic group compared to the
immediate antibiotic group (Table 2).
Delayed antibiotics versus no antibiotics
Two studies that recruited participants with sore throat compared
the prescribing strategy of delayed antibiotics with no antibiotics
(N = 1117) (De la Poza Abad 2016; Little 1997). These studies
found no evidence of difference in any clinical outcome between
these two prescribing strategies (Table 3).
Complications
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Data on complications of sore throat such as rheumatic fever, post-
streptococcal glomerulonephritis, and peritonsillar abscess were
not reported in any of the five studies evaluating sore throat for
the three prescribing strategies of immediate, delayed, and no an-
tibiotics.
Acute otitis media
Three included studies recruited participants with AOM (N =
830) (Chao 2008; Little 2001; Spiro 2006).
Delayed antibiotics versus immediate antibiotics
Two studies (N = 598) compared the prescribing strategies of
delayed antibiotics versus immediate antibiotics for AOM (Little
2001; Spiro 2006). One of these studies (N = 283) measured pain
and fever on Days 4 to 6 and found no evidence of difference
(Table 2) (Spiro 2006). In the other study (N = 315) (Little 2001),
pain and malaise on Day 3 were reported by a greater proportion
of participants randomised to the delayed antibiotics group com-
pared to the immediate antibiotics group (Table 2) (Little 2001).
Further analysis of earache from one trial found that the delayed
antibiotic prescribing strategy did not significantly increase risk of
earache at three months (OR 0.89, 95% CI 0.48 to 1.65) or one
year (OR 1.03, 95% CI 0.60 to 1.78) (Little 2006).
Delayed antibiotics versus no antibiotics
Only one study compared delayed antibiotics with no antibiotics
(N = 232) (Chao 2008). In this study, no significant difference
was detected for the outcomes of pain or fever for participants in
delayed antibiotic and immediate antibiotic groups (Table 3). This
trial also advised participants in the no antibiotic arm to return in
two to three days if symptoms did not resolve (Chao 2008).
Complications
Data on complications of AOM such as mastoiditis, rheumatic
fever, and poststreptococcal glomerulonephritis were not reported
in any of the three studies evaluating AOM for the prescribing
strategies of immediate and delayed antibiotics. However, Spiro
2006 and Chao 2008 reported that no serious adverse events had
occurred in participants in their studies (N = 515).
Bronchitis (cough)
Delayed antibiotics versus immediate antibiotics
Three studies examined the prescribing strategies of immediate
versus delayed antibiotics for the clinical presentation of cough (N
=1401) (De la Poza Abad 2016;Dowell 2001; Little 2005a).None
of the studies found any difference in clinical outcomes including
pain, fever, and cough (Table 2).
Delayed antibiotics versus no antibiotics
De la Poza Abad 2016 and Little 2005a (N = 1212) also evaluated
delayed antibiotics versus no antibiotics, finding no evidence of
difference in clinical outcomes (Table 3).
Complications
One participant in the no antibiotic group (N = 273) of one
study developed pneumonia, and recovered with antibiotics in
hospital (Little 2005a). Another study (N = 405) reported that
therewere no evidence of differences in complication rates between
the delayed and immediate antibiotic groups (De la Poza Abad
2016). The third study (N = 189) did not report on complications
in the immediate and delayed antibiotic groups (Dowell 2001).
Common cold
Delayed antibiotics versus immediate antibiotics
Two studies examined immediate antibiotics versus delayed antibi-
otics (N = 534) and found no evidence of difference between the
two prescribing strategies for fever, cough, pain, malaise, and rhi-
norrhoea except for the outcome of fever severity on Day 7 which
favoured delayed antibiotics (Table 2) (Arroll 2002a; De la Poza
Abad 2016).
Delayed antibiotics versus no antibiotics
De la Poza Abad 2016 (N = 405) compared delayed antibiotics
with no antibiotics and found a reduction in pain duration in the
patient-led prescription delayed antibiotic strategy and reductions
in fever and cough duration for both delay strategies (patient-
led prescription and prescription collection) compared with no
antibiotics (Table 3). There was no evidence of difference between
delayed and no antibiotic prescribing groups for the outcome of
nasal mucosity (Table 3).
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Pooling of clinical outcomes (delayed versus immediate
antibiotics)
Sufficient study data were available to allow the pooling of results
for the outcomes of pain (Days 3 to 6), pain severity (Day 3),
malaise (Day 3), malaise severity (Day 3), fever (Days 3 to 6),
and fever severity (Day 3) for the comparison of delayed versus
immediate antibiotics. We conducted meta-analysis for study data
where results were sufficiently homogenous.Datawere insufficient
to pool results for the comparison delayed versus no antibiotics.
Pain
There was significant heterogeneity of study data for the outcome
of pain on Days 3 to 6 (Analysis 1.1). For three studies there
was no evidence of difference examining the clinical conditions
of common cold and otitis media (Arroll 2002a; Little 2001;
Spiro 2006). One study that included participants with sore throat
favoured immediate antibiotics (El-Daher 1991).Meta-analysis for
the two studies that measured pain severity on Day 3 found in
favour of immediate antibiotics with anMD of 0.35 (95%CI 0.13
to 0.57) (Analysis 1.2).
Malaise
There was significant heterogeneity of study data for the outcome
ofmalaise onDay 3 (Analysis 2.1).However, both studies found in
favour of immediate antibiotics. One study included participants
with otitis media (Little 2001), the other participants with sore
throat (El-Daher 1991). Meta-analysis of the two studies measur-
ing malaise severity on Day 3 found in favour of immediate an-
tibiotics with an MD of 0.29 (95% CI 0.09 to 0.48) (Analysis
2.2). One of these studies recruited participants with sore throat
(Pichichero 1987), the other participantswithAOM(Little 2001).
Fever
Two studies provided data that could be combined for the out-
come of fever on Days 3 to 6 (Arroll 2002a; Spiro 2006). Meta-
analysis of these data found no evidence of difference with an OR
of 0.86 (95% CI 0.54 to 1.38) (Analysis 3.1). The three studies
providing data on fever severity on Day 3 provided heterogenous
results. One study including participants with the common cold
found no evidence of difference in fever severity on Day 3 with
an MD of -0.24 (95% CI -0.48 to -0.00) (Arroll 2002a). Two
studies found results favouring immediate antibiotics; both stud-
ies included participants with sore throat (Analysis 3.2). The first
study was Pichichero 1987 (MD 0.40, 95% CI 0.05 to 0.75), and
the second was El-Daher 1991 (MD 0.90, 95% CI 0.50 to 1.30)
(Analysis 3.2).
2. Antibiotic use
Delayed antibiotics versus immediate antibiotics
The three included studies published before 1992 investigated the
concern that immediate antibiotics for streptococcal pharyngitis
might impair the body’s immune response and predispose the pa-
tient to a relapse of pharyngitis (El-Daher 1991; Gerber 1990;
Pichichero 1987). Antibiotic use in both immediate and delayed
antibiotic groups was close to 100% as intended. Seven of the
included studies published after 1992 (N = 2840) evaluated de-
layed antibiotics as a way to reduce antibiotic use for respiratory
infections compared to immediate antibiotics (Arroll 2002a; De
la Poza Abad 2016; Dowell 2001; Little 1997; Little 2001; Little
2005a; Spiro 2006). All seven studies found that antibiotic use was
significantly reduced in the delayed antibiotic group compared to
the immediate antibiotic group. There were significant differences
in the way antibiotics were delayed, which may have resulted in
the marked heterogeneity of this result. Of the eight studies pub-
lished after 1991, four had the delayed script kept at reception to
be picked up (N = 2023) (Dowell 2001; Little 1997; Little 2001;
Little 2005a), while in three the script was issued to patients with
instructions to delay (N = 644) (Arroll 2002a; Chao 2008; Spiro
2006). De la Poza Abad 2016 was specifically designed to deter-
mine the relative efficacy and safety of two delayed strategies: one
where the delayed script was kept at the primary care centre to
be picked up (prescription collection) and one where the script
was issued to patients with instructions to delay (patient-led pre-
scription). For the delayed arms of the five studies where the script
was left at reception, antibiotics were used in 27% of cases (196/
718) compared with use of antibiotics in 38% of cases (154/403)
where antibiotics were issued to patients with instructions to delay
(Analysis 4.1). One included study compared delayed antibiotics
with no antibiotics and did not include an immediate antibiotic
prescribing arm (Chao 2008). Of the eight trials conducted af-
ter 1992 that included a delayed antibiotic arm, we found 350
prescriptions filled out for 1121 participants (31.2%) (Analysis
4.1). Pooled results of these studies showed that delayed antibiotics
resulted in a significant reduction in antibiotic use compared to
immediate antibiotics (OR 0.04, 95% CI 0.03 to 0.05) (Analysis
4.1). This evidence is moderate quality according to GRADE as-
sessment (Summary of findings for the main comparison).
Seven trials published after 1992 provided immediate antibiotic
arms measuring this outcome, resulting in 882 out of 948 partic-
ipants (93.0%) filling prescriptions (Analysis 4.1).
Delayed antibiotics versus no antibiotics
Four studies compared delayed antibiotics with no antibiotics (N
= 1241) (Chao 2008; De la Poza Abad 2016; Little 1997; Little
2005a). Pooled results of these studies showed that 77 out of 564
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participants in the no antibiotic arms filled scripts (13.7%). More
participants in the delayed antibiotic groups filled prescriptions
comparedwith the no antibiotic groups (OR2.55, 95%CI 1.59 to
4.08) (Analysis 4.2). This evidence is moderate quality according
to GRADE assessment (Summary of findings 2).
3. Patient satisfaction
Delayed antibiotics versus immediate antibiotics
Patient satisfaction was measured in six (of eight) studies since
1992 (N = 1663) that evaluated delayed prescribing (Analysis 5.1)
(Arroll 2002a; De la Poza Abad 2016; Dowell 2001; Little 1997;
Little 2001; Little 2005a). The pooled result for all six studies
showed no evidence of difference between the number of partic-
ipants in the delayed antibiotic group who were satisfied or very
satisfied compared to the immediate antibiotic group (OR 0.65,
95% CI 0.39 to 1.10) (Analysis 5.1). For the same outcome, we
obtained a similar OR of 0.62 (95% CI 0.38 to 1.01) for the
three studies that included elements of blinding (N =1125) (Arroll
2002a; Dowell 2001; Little 2005a). Similarly, the three studies
without any blinding (N = 1432) found anOR for this outcome of
0.64 (95% CI 0.27 to 1.55) (De la Poza Abad 2016; Little 1997;
Little 2001). For the six studies addressing this outcome, 91%
of participants in the immediate antibiotics arms were satisfied or
very satisfied compared with 86% of participants in the delayed
antibiotics arms. The one study that involved only child partic-
ipants found in favour of immediate antibiotics, with an OR of
0.32 (95% CI 0.16 to 0.65) (Little 2001). These results are based
on moderate-quality evidence according to GRADE assessment
(Summary of findings for the main comparison).
Delayed antibiotics versus no antibiotics
Four studies examined patient satisfaction for delayed antibiotics
compared with no antibiotics (N = 1234) (Chao 2008; De la Poza
Abad 2016; Little 1997; Little 2005a). The pooled result of all
four studies showed that more participants were satisfied or very
satisfied in the delayed antibiotic group compared with the no
antibiotic group (OR 1.49, 95% CI 1.08 to 2.06) (Analysis 5.2).
The number needed to treat with delayed antibiotics rather than
no antibiotics to achieve a satisfied or very satisfied patient is 22.5.
Fixed-effect and random-effects analyses gave similar results. The
two trials that blinded the outcome assessor found a similar OR
for this outcome (OR 1.42, 95% CI 0.92 to 2.19) (N = 1039)
(Chao 2008; Little 2005a). Similarly, the two unblinded trials
found an OR of 1.58 (95% CI 0.97 to 2.55) (N = 1117) (De la
Poza Abad 2016; Little 1997). For the four studies addressing this
outcome, 87% of participants in the delayed antibiotic group were
satisfied or very satisfied compared with 82% in the no antibiotics
group. The one study that involved only child participants found
no evidence of difference, with an OR of 2.00 (95% CI 0.65 to
6.18) (Chao 2008). These results are based on moderate-quality
evidence according to GRADE assessment (Summary of findings
2).
4. Antibiotic resistance
None of the included studies evaluated antibiotic resistance.
Secondary outcomes
1. Adverse effects of antibiotics
Seven studies reported on the adverse effects of antibiotics (N =
2707) (Arroll 2002a; Chao 2008; El-Daher 1991; Little 1997;
Little 2001; Little 2005a; Spiro 2006).
Delayed antibiotics versus immediate antibiotics
Heterogeneity of outcomes for adverse events may be due to dif-
ferences in antibiotic prescribing recommendations for different
RTIs. This is likely to have contributed to the heterogeneity evi-
dent for these outcomes, preventing pooling of results except for
the outcome of rash, for which there was no significant differ-
ence (OR 1.03, 95% CI 0.54 to 1.97). Overall results for ad-
verse effects comparing delayed and immediate antibiotics are pre-
sented for the outcomes of vomiting (N = 888) (Analysis 6.1), di-
arrhoea (N = 1073) (Analysis 6.2), and rash (N = 1027) (Analysis
6.3). The evidence presented below is low quality evidence ac-
cording to GRADE assessment owing to concerns about bias from
lack of blinding, concerns about allocation concealment, and het-
erogeneity of outcome data (Summary of findings for the main
comparison).
Sore throat
Little 1997 found no evidence of difference for diarrhoea, vom-
iting, rash, and stomachache for participants in delayed and im-
mediate antibiotic groups. El-Daher 1991 found more vomiting
associated with delayed compared to immediate antibiotics.
Acute otitis media
Little 2001 and Spiro 2006 found reduced diarrhoea in the delayed
antibiotic group. Spiro 2006 found no evidence of difference be-
tween delayed and immediate antibiotics for vomiting, and Little
2001 found no evidence of difference for rash.
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Cough
Little 2005a found no evidence of difference for adverse effects.
Common cold
There was no significant difference between delayed and imme-
diate antibiotic groups for diarrhoea, a potential adverse effect of
antibiotics (Arroll 2002a).
Delayed antibiotics versus no antibiotics
There were too few studies measuring adverse effects of antibi-
otics for the comparison of delayed versus no antibiotics to jus-
tify pooling results. Little 1997 (N = 712) found no evidence of
difference for the outcome of vomiting in participants with sore
throat (OR 0.68, 95% CI 0.34 to 1.36). Little 1997 also found
no evidence of difference for the outcome of diarrhoea (OR 1.57,
95% CI 0.80 to 3.07). In the study by Chao 2008 (N = 232) of
children with AOM there were no reports of diarrhoea in either
the delayed or no antibiotics group. Little 1997 found no evidence
of difference for the outcome of rash between delayed antibiotics
and no antibiotics (OR 0.51, 95% CI 0.24 to 1.10). These results
were assessed as moderate-quality evidence according to GRADE
assessment (Summary of findings 2).
2. Complications of disease
There was no significant difference in complication rates between
the three prescribing strategies. Five studies reported on compli-
cations or serious adverse effects (N = 1856) (Arroll 2002a; Chao
2008; De la Poza Abad 2016; Little 2005a; Spiro 2006). More
details of disease complications are reported above under clinical
outcomes for each disease category.
3. Reconsultation rates
Reconsultation rates were similar between delayed and immediate
antibiotic groups in two studies. Pooling resulted in an OR of
1.04 (95% CI 0.55 to 1.98) (N = 379) (Analysis 7.1). Subsequent
consultation rates in the 12 months (excluding the first month)
were also similar between delayed and immediate antibiotic groups
in one study (Little 2001). Participants with sore throat in one
study were more likely to intend to consult again if they received
immediate antibiotics compared to those who received delayed an-
tibiotics (Little 1997). These results are based on moderate quality
evidence according to GRADE assessment (Summary of findings
for the main comparison).
4. Use of other therapies
Three studies reported onuse of othermedicines (N=1802) (Little
1997; Little 2001; Spiro 2006). In one study (Little 1997), there
was no evidence of difference in analgesic use for participants with
sore throat presenting to primary care in immediate, delayed, and
no antibiotic prescribing groups. Two studies looked at analgesic
use in children with AOM. One study evaluating children pre-
senting to primary care found less paracetamol was consumed in
the immediate antibiotic group compared with the delayed antibi-
otic group (Little 2001). The other study, which evaluated chil-
dren presenting to an emergency department, found no evidence
of difference between groups in paracetamol and ibuprofen use
(Spiro 2006).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Delayed antibiotics compared to no antibiotics for respiratory infections
Patient or population: respiratory infect ions
Setting: Primary care, emergency department
Intervention: delayed ant ibiot ics
Comparison: No ant ibiot ics
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no antibiotics Risk with delayed antibi-
otics
Clinical outcomes (clin-
ical outcomes)
assessed with: pain,
fever, cough, nasal mu-
cosity,
follow-up: range 1 days
to 16 days
4 studies measured clinical outcomes for this
comparison. 2 studies recruited part icipants with
sore throat, one study recruited part icipants with
ot it is media, and 1 study recruited part icipants
with cough, and for these studies there was no
evidence of dif f erences found. 1 study recruited
part icipants with the common cold, and found re-
sults favouring delayed ant ibiot ics for pain, fever,
and cough durat ion, but no evidence of dif f er-
ence for nasal mucosity
- 955
(4 RCTs)
⊕⊕⊕©
MODERATE
1
Antibiot ic use: delayed
versus no ant ibiot ics
137 per 1,000 287 per 1,000
(201 to 392)
OR 2.55
(1.59 to 4.08)
1241
(4 RCTs)
⊕⊕⊕©
MODERATE
1
Patient sat isfact ion: de-
layed versus no ant ibi-
ot ics
824 per 1,000 875 per 1,000
(835 to 906)
OR 1.49
(1.08 to 2.06)
1235
(4 RCTs)
⊕⊕⊕©
MODERATE
1
Adverse ef fects of an-
t ibiot ics (adverse ef -
fects)
assessed with: vomit-
ing, diarrhoea, rash,
2 studies measured adverse ef fects. 1 recruited
part icipants with sore throat, and 1 with ot it is
media. Neither study found any dif ference in
adverse ef fects
- 566
(2 RCTs)
⊕⊕⊕©
MODERATE
1
2
1
D
e
la
y
e
d
a
n
tib
io
tic
p
re
sc
rip
tio
n
s
fo
r
re
sp
ira
to
ry
in
fe
c
tio
n
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
9
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
f ollow-up: range 1 days
to 7 days
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded 1 level for inadequate blinding for all studies, and allocat ion concealment not adequately reported for more
than half of studies
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D I S C U S S I O N
Summary of main results
Results for clinical outcomes were often heterogeneous. For most
outcomes there was no evidence of difference between delayed an-
tibiotics and both immediate and no antibiotic prescribing strate-
gies. Insufficient data precluded pooling of study data for the
comparison of delayed and no antibiotics. Where data could be
pooled for the strategies of delayed and immediate antibiotics, re-
sults favoured immediate antibiotics for pain severity on Day 3
(participants presented with otitis media and sore throat) and
malaise severity on Day 3 (participants presented with otitis me-
dia and sore throat). There was no evidence of differences in the
number of participants with fever on Days 3 to 6 (participants
presented with the common cold and otitis media). All strategies
appear to have similar safety with no advantage for delayed an-
tibiotics over either no antibiotics or immediate antibiotics for dis-
ease complications. delayed and no antibiotic strategies markedly
reduced the use of antibiotics for RTIs compared to immediate
antibiotics. The least antibiotic use was in the no antibiotic group,
followed by delayed and then immediate antibiotic groups. The
number needed to treat to prevent one antibiotic prescription us-
ing the delay strategy was 1.6 compared to immediate antibiotics.
The number needed to treat to prevent one antibiotic prescrip-
tion using a no antibiotic strategy compared to a delayed antibiotic
strategy was 7.0. Patient satisfaction was highest in the immedi-
ate antibiotic group, with 91% being moderately satisfied, very
satisfied, or extremely satisfied with the consultation. The delayed
antibiotic group was more satisfied (87%) than the no antibiotic
group (83%). These high satisfaction results may reflect patient
involvement in studies, where treating physicians were more thor-
ough in their explanations than usual (Hawthorne effect) (French
1950; Levitt 2011). No data were available regarding antibiotic
resistance.
Overall completeness and applicability of
evidence
Studies comparing delayed and immediate antibiotics have been
performed with two different motives. The studies of Pichichero
1987, Gerber 1990, and El-Daher 1991 were concerned that im-
mediate antibiotics for streptococcal pharyngitis might impair the
body’s immune response and predispose the patient to a relapse of
pharyngitis. These studies are useful for determining the effect of
delayed versus immediate antibiotics on the clinical course of sus-
pected streptococcal pharyngitis. Seven of the remaining studies
were conducted to determine if the strategy of delayed antibiotics
reduces the number of prescriptions filled for RTIs while main-
taining patient safety and satisfaction (Arroll 2002a; De la Poza
Abad 2016; Dowell 2001; Little 1997; Little 2001). The most
recent study, De la Poza Abad 2016, further aimed to explore the
relative efficacy and safety of two delayed prescribing strategies.
Useful data were collected for many symptom outcomes in all
studies but were not always reported in a way that could be anal-
ysed or compared with other studies. This problem was partially
overcome by obtaining rawdata from some trial authors. The eight
studies conducted after 1992 all reported useful data on antibiotic
use, and seven reported useful data on patient satisfaction.
Four trials compared delayed antibiotics with no antibiotics.
There were no data on levels of antibiotic resistance.
Quality of the evidence
All but one trial, El-Daher 1991, were adequately randomised and
accounted for incomplete data. El-Daher 1991 did find large dif-
ferences for clinical outcomes for sore throat in favour of immedi-
ate antibiotics compared to delayed antibiotics.
The assessed interventions did not lend themselves to blinding.
However, three trials attempted to blind participants and doctors
(Arroll 2002a; El-Daher 1991; Pichichero 1987). In four studies
the outcomes assessor was blinded, but neither participants nor
caregivers were blinded (Chao 2008; Dowell 2001; Little 2005a;
Spiro 2006).
Otherwise, studies were well reported. The GRADE assessments
of the meta-analyses of outcomes for antibiotic use and patient
satisfaction were moderate (Summary of findings for the main
comparison; Summary of findings 2). GRADE assessments of
clinical outcome data and reconsultation rates were moderate
(Summary of findings for the main comparison, Summary of
findings 2). GRADE assessments of adverse effects of antibiotics
for the comparison of delayed antibiotics versus immediate antibi-
otics was low owing to concerns about lack of blinding, inadequate
reporting of allocation concealment, and heterogeneity of results
(Summary of findings for the main comparison).
Potential biases in the review process
Heterogeneity of RCTs was one limitation of this review. Hetero-
geneity may have resulted from variable clinical presentations, dif-
ferences in delay method, differences in antibiotic use, and quality
of included studies. Potential for type I error (falsely positive re-
sults) is another limitation of this review given the large number of
reported clinical outcome results. For example, multiple outcome
measures are reported for the clinical outcomes comparing delayed
and immediate antibiotic groups.
Agreements and disagreements with other
studies or reviews
Findings for certain clinical outcomes may have been anticipated.
Systematic reviews on antibiotics for sore throat and AOM found
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that the time of greatest benefit for symptoms is apparent at Days
3 or 4 after treatment was started (Spinks 2013; Venekamp 2015).
Delaying antibiotics by 48 hours or more would thus overshoot
this zenith. Nor is it surprising that we found more adverse reac-
tions to antibiotics from immediate antibiotics in line with known
adverse events from comparison RCTs with no antibiotics.
We found the greatest difference in clinical outcomes in the only
trial of delayed antibiotics conducted in a country not considered
to be a high-income economy according to theWorld Bank at the
time of publication (World Bank 2017). El-Daher 1991 favoured
immediate antibiotics over delayed antibiotics. This trial was also
the least methodologically sound, but it highlighted that concerns
expressed about delayed antibiotics for children, the elderly, and
those with language or cultural difficulties may also need to be ex-
tended to lower socioeconomic populations (Datta 2008; Johnson
2007).
A parallel RCT of people with acute infective conjunctivitis simi-
larly reported shortest symptom duration with immediate antibi-
otics, followed by delayed and then no antibiotics (the last result-
ing in least antibiotic use). There was no evidence of difference
between groups for patient satisfaction (Everitt 2006).
Worrall 2010 compared delayed prescriptions dated either the day
of the office visit or two days later, but did not compare delayed
with either immediate or no antibiotics. This study demonstrated
no significant difference between groups in terms of antibiotic use.
Randomised controlled trials comparing delayed with no antibi-
otics and concluding that they were both acceptable alternatives
to immediate antibiotics as a means of reducing antibiotic pre-
scriptions led to a recommendation for delayed instead of no an-
tibiotics to address concerns about risks of complications (Little
2001; Little 2005a; Little 2005b). Doctors worried about the risk
of serious infective complications consequent to adopting a no an-
tibiotic rather than delayed antibiotic strategy might take comfort
from a UK observational study showing that reduced prescribing
resulted in no increase in admissions to hospital for peritonsillar
abscess or rheumatic fever (Sharland 2005), although mastoiditis
might be a risk at the rate of 2500 children needing to be treated
with antibiotics to prevent one case (Van Zuijlen 2001). Just over
a third (35%) of parents in the AOM trials used their delayed
script, suggesting that the number of delayed scripts required to
prevent one case of mastoiditis would be significantly higher than
2500 (Chao 2008; Little 2001; Spiro 2006). A large cohort study
(28,883 participants) recruiting people with symptoms and signs
of lower RTI found no evidence of difference in hospitalisation
or death regardless of antibiotic prescribing strategies, which in-
cluded immediate, delayed, and no antibiotics (Little 2017). Doc-
tors often find it difficult to identify patients at risk of serious
complications from respiratory infections (Kumar 2003). Patients
probably perform even less well, despite their self confidence in
making this decision if given a delayed antibiotic prescription. This
concern is supported by empirical data: respiratory disease sever-
ity does not correlate with patients’ immediate preference for an
antibiotic prescription (Macfarlane 1997). We did not find any
significant difference for complication rates between prescribing
strategies.
There is little controversy within published guidelines that imme-
diate antibiotics are recommended for patients who appear to be
seriously unwell, fitmultiple criteria indicating bacterial tonsillitis,
are under six months of age with AOM, have bilateral AOM, or
have AOM with otorrhoea (Tan 2008). American guidelines also
recommend immediate antibiotics for children under the age of
two with definite AOM (OMTG 2004). It seems then that for the
majority of respiratory infections that do not meet these criteria,
clinicians have the option of delayed or no antibiotics. Where doc-
tors are confident in not prescribing antibiotics, it seems clear that
no antibiotics will result in the least antibiotic use, and therefore
less antibiotic resistance. Concerns about patient and doctor satis-
faction with no antibiotics appear to be driving the use of a delayed
strategy. Some doctors use the delay strategy to reduce antibiotic
use, empower patients, and save the patient time and money with-
out jeopardising the doctor-patient relationship (Arroll 2002b). A
qualitative study found that while some participants appreciated
the option of controlling the decision as to whether and when to
take antibiotics, others expected “the physician to decide” (Arroll
2002b).One physician expressed concern that patientsmight view
delayed prescribing as physician incompetence, whichwas substan-
tiated by comments from some patients. In this review, we found
higher levels of patient satisfaction with a strategy of delayed an-
tibiotics compared with no antibiotics (number needed to treat for
an additional beneficial outcome: 22.5 patients). Shared decision-
making and education campaigns for doctors have been proposed
as ways of helping doctors and patients avoid unnecessary antibi-
otic use (Butler 2001; Legare 2007; Sung 2006). One suggestion
is that delayed antibiotics may in time become redundant as doc-
tors and their patients become more reassured of the safety of not
using antibiotics (Arroll 2003b). Meanwhile, a delayed antibiotics
strategy may be an acceptable compromise to reduce antibiotics
prescribing for RTIs and thereby reduce antibiotic resistance.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A strategy ofimmediate antibiotics is more likely to confer the
modest benefits of antibiotics on clinical outcomes such as symp-
toms for acute otitis media and sore throat than delayed antibiotics
(moderate quality evidence according to GRADE assessment).
There was no evidence of differences in complication rates be-
tween immediate and delayed antibiotics or between delayed and
no antibiotics. Immediate antibiotics had similarly high levels of
patient satisfaction to delayed antibiotics (91% versus 86% -mod-
erate quality evidence according to GRADE assessment). Delayed
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antibiotics had higher levels of patient satisfaction than no an-
tibiotics (87% versus 82% - moderate quality evidence according
to GRADE assessment). Delayed antibiotic prescribing strategies
achieved markedly lower rates of antibiotic use compared to im-
mediate antibiotics (31% versus 93% - moderate quality evidence
according to GRADE assessment). Requiring the patient to return
for a prescription resulted in even lower antibiotic use (27%) than
giving a prescription at the time of the consultation with instruc-
tions to fill the prescription if symptoms worsened (38%). No an-
tibiotics achieved lower rates still of antibiotic use compared to
delayed antibiotics (14% versus 28% - moderate quality evidence
according to GRADE assessment).
Delayed antibiotics for respiratory infections is a strategy that re-
duces antibiotic use compared to immediate antibiotics, maintains
similar patient satisfaction to immediate antibiotics, and does not
result in greater numbers of complications compared with imme-
diate antibiotics. Delayed antibiotics results in more antibiotic use
than no antibiotics, but also slightly greater patient satisfaction
compared to no antibiotics, and minimal differences for symptom
control and complications compared with no antibiotics.
In patients with respiratory infections where clinicians, informed
by relevant guidelines, feel it is safe not to prescribe antibiotics
immediately, no antibiotics with advice to return if symptoms do
not resolve results in the least antibiotic use, while maintaining
high levels of patient satisfaction and patient safety. Where clini-
cians are not confident in using a no antibiotic strategy, a delayed
antibiotics strategy may be an acceptable compromise in place of
immediate prescribing to significantly reduce unnecessary antibi-
otic use for respiratory tract infections, and thereby reduce antibi-
otic resistance, without significantly compromising patient safety
or satisfaction levels.
Implications for research
Further research into antibiotic prescribing strategies for respira-
tory infections may best be focused on identifying patient groups
at high risk of disease complications, enhancing doctors’ com-
munication with patients to maintain satisfaction, ways of reduc-
ing doctors’ anxieties about not prescribing antibiotics for respira-
tory infections, and policy measures to reduce unnecessary antibi-
otic prescribing for respiratory tract infections. Future randomised
controlled trials of delaying antibiotics as an intervention should
fully report symptoms, patient satisfaction, doctor satisfaction,
and disease complications as well as changes in prescription rates.
They should also include a no antibiotic arm. Measurement and
reporting of antibiotic resistance would also be welcome in this
setting.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arroll 2002a
Methods Randomised controlled trial over 3 months
Participants 129 adults and children with the common cold presenting to primary care services in
Auckland, New Zealand
62 participants were randomised to immediate antibiotic prescription, and 69 to delayed
antibiotic prescription
Age: the average age was 27.9 years (SD 3.1) in the immediate antibiotic group and 23.
6 years (SD 2.7) in the delayed antibiotic group.
Gender: immediate antibiotic group: 22 males out of 40; delayed antibiotic group: 26
males out of 41
Exclusion criteria included suspected streptococcal tonsillitis, sinusitis, bronchitis,
pneumonia, lower respiratory signs, need for X-ray, history of rheumatic fever, serious
illness, or any antibiotic treatment in the previous 2 weeks
Interventions Delayed antibiotics (participants given script and instructed to fill within 72 hours) versus
immediate antibiotics
Outcomes Primary outcomes: participant diaries were used to measure fever, duration of fever,
cough, duration of cough, pain, antibiotic use, and patient satisfaction
Secondary outcomes: absence from school/work, diarrhoea, adverse effects of antibi-
otics, antibiotic use, and patient satisfaction
Notes Funding source: Health Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation
Allocation concealment (selection bias) Low risk Opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patient and care provider were blinded, but
unsure regarding outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was used and
dropouts were reported. 62 out of 67 par-
ticipants in the delayed antibiotic arm and
61 out of 62 participants in the immediate
antibiotic arm completed the trial
Selective reporting (reporting bias) Low risk Prespecified outcomes were reported.
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Arroll 2002a (Continued)
Other bias Low risk Funded by government grant
Chao 2008
Methods Randomised controlled trial for 12 months
Participants 232 children with AOM presenting to 1 paediatric emergency department in an urban
public hospital in the Bronx, NewYork, USA.Data were obtained from 206 participants,
of which 100 were randomised to observation (no antibiotics) and 106 were randomised
to delayed antibiotic prescription.
Age: median age in the no antibiotic group was 5.0 years (IQR 3.7 to 6.7) and in the
delayed antibiotic group was 3.7 years (IQR 2.8 to 5.8).
Gender: 47 males (47%) in the no antibiotic group and 60 males (57%) in the delayed
antibiotic group
Exclusion criteria: children were excluded if they had a history of immunodeficiency,
craniofacial abnormalities, were already taking antibiotics, had concurrent bacterial in-
fection requiring antibiotic treatment, no telephone contact, AOM in last 30 days, pain
did not settle with analgesia after 30 minutes, or 48 hours of otalgia and fever
Interventions No antibiotics (observation) versus delayed antibiotics (observation plus prescription).
Participants in the delayed antibiotic groupwere given a script, which theywere instructed
to fill if needed
Outcomes Primary outcomes: data on fever, pain, antibiotic use, and patient satisfaction were col-
lected by a research assistant during a phone call 7 to 10 days after the initial presentation
Secondary outcomes: adverse events were collected by a research assistant during a
phone call 7 to 10 days after the initial presentation
Notes The funding source for this study was not described.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Outcome assessor blinded. Study authors
did not indicate if participant and care
provider were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were described and ITT anal-
ysis applied. 232participantswere correctly
enrolled, and 206 completed the final in-
terview
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Chao 2008 (Continued)
Selective reporting (reporting bias) Low risk Prespecified outcomes were reported.
Other bias Unclear risk Funding not described.
De la Poza Abad 2016
Methods Randomised controlled trial over 2.5 years
Participants 405 adults with uncomplicated respiratory infections presenting to 23 primary healthcare
centres in Spain. 398 participants were randomised, 198 to delayed antibiotics (100
to prescription collection strategy and 98 to patient-led prescription strategy), 101 to
immediate antibiotics, and 99 to no antibiotics.
Age: the average age of participants in the prescription collection delayed antibiotic
strategy was 42 years (SD 17); the patient-led prescription delayed antibiotic strategy 45
years (SD 17); the immediate antibiotic group 48 years (SD 17); and the no antibiotic
group 45 years (SD 16)
Gender: there were 29 men (29%) in the prescription collection delayed antibiotics
group; 33 men (34%) in the patient-led prescription delayed antibiotics group; 39 men
(39%) in the immediate antibiotic group; and 35 men (35%) in the no antibiotic group
Exclusion criteria: not reported
Interventions Delayed antibiotics (patient-led prescription strategy) versus delayed antibiotics (prescrip-
tion collection strategy) versus immediate antibiotics versus no antibiotics
Outcomes Primary outcomes: duration of symptoms, severity of symptoms, antibiotic use, patient
satisfaction
Secondary outcomes: participants’ beliefs about the effectiveness of antibiotics
All outcomes were measured using a patient diary.
Notes Grant funding came from a joint initiative of the Spanish federal government and the
European Regional Development Fund. Study authors were approached for extra infor-
mation and these data were obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were centrally randomised us-
ing an e-online platform
Allocation concealment (selection bias) High risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding undertaken.
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De la Poza Abad 2016 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 405 participants were recruited and 398 in-
cluded in the analysis; 3 lost to follow-up in
delayed group, 4 lost to follow-up in the im-
mediate/no prescription group. Intention-
to-treat guided all analyses
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk Funded by government body.
Dowell 2001
Methods Randomised controlled trial over 1 year
Participants 191 adults and children presenting with cough to 22 general practices in Scotland
99 participants were randomised to delayed antibiotics, and 92 to immediate antibiotics.
Age: the average age of participants in the delayed antibiotic group was 39.3 years, and
in the immediate antibiotic group 43.8 years
Gender: 43 of 99 participants in the delayed antibiotic group were men; 34 of 92
participants in the immediate antibiotic group were men
Exclusion criteria: potential participants were excluded if the general practitioner would
not consider offering antibiotics, or if the patient expressed a strong preference for an-
tibiotics. Other exclusion criteria included people with chest signs, immunosuppression,
pre-existing lung disease, diabetes, and patients who could not return to their general
practice
Interventions Participants were randomised to delayed antibiotics (script left at reception and partic-
ipants instructed to pick up the script after 1 week of delay) or immediate antibiotics
(antibiotic of general practitioner’s choice).
Outcomes Baseline data were collected by the general practitioner. The participants were also asked
to fill out a diary at home for 14 days regarding their symptoms
Primary outcomes: outcomemeasures included duration of cough, fever, breathlessness,
runny nose, antibiotic use, and patient satisfaction
Notes The study was funded by a grant from the Royal College of General Practitioners
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Numbered envelopes (opacity not men-
tioned)
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Dowell 2001 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Outcome assessor blinded. Blinding of par-
ticipant and care provider not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout numbers were described, and ITT
analysis used. Of 191 participants, 148 re-
turned questionnaires describing clinical out-
comes and patient satisfaction
Selective reporting (reporting bias) Low risk Prespecified clinical outcomes were not pub-
lished, but authors provided this information
Other bias Low risk Funded by Royal College of General Practi-
tioners.
El-Daher 1991
Methods Randomised controlled trial over 13 months
Participants 229 children with sore throat (suspected GABHS) presenting to the paediatric clinics of
the University of Science and Technology in Jordan. Children were included if they had
at least 3 of the 5 following signs of (1) fever greater than 38 °C, (2) tonsillar exudate/
beefy red throat, (3) cervical lymph node tenderness, (4) sore throat associated with
difficulty swallowing, and (5) systemic toxicity. The study enrolled 306 participants, but
only randomised the 229 who were culture-positive
Age: of the 111 participants randomised to the immediate antibiotic group, the average
age was 7.8 years (SD 2.4); of the 118 participants randomised to the delayed antibiotic
group, the average age was 8.3 years (SD 2.6)
Gender: 60 of the 111 participants in the immediate antibiotic group were male; 66 of
the 118 participants in the delayed antibiotic group were male
Exclusion criteria: childrenwere excluded if they had any of penicillin allergy, antibiotics
in preceding 7 days, acute illness in preceding 7 days, GABHS infection in preceding
month, and concurrent infection requiring treatment with an antibiotic that was not
penicillin
Interventions Delayed antibiotics (48-hour delay) versus immediate antibiotics for 10 days (penicillin
V 50,000 IU/kg/day in 3 divided doses)
Outcomes Primary outcomes: outcome measures included pain, malaise, vomiting, temperature
Secondary outcome: infection recurrence
Notes This study was supported by both Biochemie GmbH and Jordan University of Science
and Technology. We approached the study authors for additional information, but did
not receive a reply
Risk of bias
Bias Authors’ judgement Support for judgement
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El-Daher 1991 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) High risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of participant and care provider,
but unsure about outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts not described
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias High risk Funded by Biochemie GmbH and Jordan
University of Science and Technology
Gerber 1990
Methods Randomised controlled trial over 6 months
Participants 113 adolescents and children with sore throat (suspected GABHS) presenting to a private
paediatric office in Connecticut, USA
Age: the average age of the 63 participants randomised to delayed antibiotics was 9.5
years; of the 50 participants randomised to immediate antibiotics it was 8.1 years.
Gender: 30 of the 63 participants in the delayed antibiotics group were male; 29 of the
50 participants in the immediate antibiotics group were male.
Exclusion criteria: hypersensitivity to penicillin, had received penicillin in the previous
72 hours, or had a negative throat culture
Interventions Both groups received 250 mg of penicillin V 3 times a day for 10 days. Participants
randomised to delayed antibiotics received their prescription 48 hours later than those
randomised to immediate antibiotics.
Outcomes Primary outcomes: symptoms were measured but not reported.
Secondary outcomes: recurrence rate. Symptoms were measured but not reported.
Notes Funding sources for this trial were not reported. We approached the authors for trial
data, but did not receive a reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) High risk No information
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Gerber 1990 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts were described. 63 out of 63 par-
ticipants in the delayed antibiotic group re-
turned for a follow-up visit after 4 days. 49
out of 50 participants in the immediate an-
tibiotic group returned for follow-up visit
at 4 days
Selective reporting (reporting bias) Unclear risk Clinical outcomes reported as 1 outcome.
Other bias Unclear risk Funding not described.
Little 1997
Methods Open randomised controlled trial over 20 months
Participants 712 adults and children with sore throat presenting to 11 general practices in England,
UK. Of these 712 participants, 235 were randomised to delayed antibiotics.
Age: of the 235 participants randomised to delayed antibiotics, 181 were older than 12
years; of the 246 participants randomised to immediate antibiotics, 187 were older than
12 years; and of the 232 participants randomised to no antibiotics, 173 were older than
12 years.
Gender: 82 of the 235 participants in the delayed antibiotics group were male; 95 of
the 246 participants in the immediate antibiotics group were male; and 82 of the 232
participants in the no antibiotics group were male.
Exclusion criteria: people were excluded if they had a sore throat that was clearly not a
bacterial infection, e.g. due to drugs, aphthous ulcers, candidal infection.Other exclusion
criteria included being very unwell, suspected or previous rheumatic fever, multiple
(more than 5 per year) attacks of tonsillitis, quinsy, and pregnancy
Interventions Participants in the delayed antibiotics group were instructed to pick up a script left at
reception after 72 hours if needed. Participants in the immediate antibiotics group were
immediately offered a script for antibiotics. The antibiotic prescription for both groups
was penicillin V 250 mg 4 times a day for 10 days. For children aged 3 to 5 years, the
dose was reduced to 125 mg. Participants who were penicillin allergic received a script
for erythromycin with the same dosing regimen as for penicillin. Participants in the no
antibiotics group were not offered antibiotics.
Outcomes Primary outcomes: fever, cough, duration of pain, and duration of malaise. Antibiotic
use and patient satisfaction were measured
Secondary outcomes: absences from school, diarrhoea, stomachache, rash
Outcomes were assessed using a patient diary and a follow-up telephone call from a
research assistant
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Little 1997 (Continued)
Notes This study was supported by Wessex NHS regional research and development funds.
We approached the authors for study data, which they provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not described.
Allocation concealment (selection bias) Unclear risk “Sealed envelopes”, but no mention of
opacity
Blinding (performance bias and detection
bias)
All outcomes
High risk This study was described as an open ran-
domised trial, so no blinding was used
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis conducted. In
the delayed antibiotic group, 179 partici-
pants responded out of 235. In the imme-
diate antibiotic group, 215 participants re-
sponded out of 246. In the no antibiotic
group, 186 participants responded out of
231
Selective reporting (reporting bias) Low risk Outcomeswere reported as indicated in the
methods section.
Other bias Low risk Funded by government body
Little 2001
Methods Pragmatic randomised controlled trial conducted over an unknown period of time
Participants 315 children aged 6 months to 10 years with AOM were recruited by 42 general practi-
tioners in England, UK. 164 of the 315 children were randomised to delayed antibiotics.
Age: of the 164 children in the delayed antibiotics group, 93 were older than 3 years of
age; of the 151 children in the immediate antibiotics group, 93 were older than 3 years.
Gender: not provided
Exclusion criteria: children were excluded if they had a pink tympanic membrane
only, and otoscopic appearances consistent with otitis media with effusion and chronic
suppurative otitis media according to the treating general practitioner. Children were
also excluded if they had a serious chronic disease, needed antibiotics for an ear infection
in the preceding 2 weeks, had previous complications, or if the child was too unwell for
a delay in antibiotics. Children were judged to be too unwell if they had a high fever,
were floppy, drowsy, and/or not responding to antipyretics
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Little 2001 (Continued)
Interventions The parents of children in the delayed antibiotics group were advised to use the antibiotics
script they had been given if their child had significant otalgia or fever after 72 hours,
or if discharge lasted for 10 days or more. Alternatively, children were randomised to
immediate antibiotics. The antibiotic prescription was amoxicillin syrup (125 mg in 5
mL) 3 times a day for 1 week in each group unless the child was penicillin allergic. The
exact dosage depended on the age of the child. Children who were penicillin allergic
were prescribed erythromycin (125 mg in 5 mL) 4 times a day for 1 week in a dose
appropriate to their age
Outcomes Outcomes were measured using a patient diary.
Primary outcomes: fever, severity of pain, duration of malaise, antibiotic use, patient
satisfaction, further earache at 3 and 12 months
Secondary outcomes: absence from school, use of paracetamol
Notes We approached the study authors for original study data, but theywere unable to provide
these data. This study was funded by the UK National Health Service
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomised to a
group”
Allocation concealment (selection bias) Low risk Quote: “doctor opened a sealed numbered
opaque envelope”
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding undertaken.
Incomplete outcome data (attrition bias)
All outcomes
Low risk A comparison of responders versus non-re-
sponders was undertaken. 150 of 164 par-
ticipants in the delayed antibiotics group
hadoutcomedata analysed; 135of 151par-
ticipants in the immediate antibiotics group
had outcome data analysed.
Selective reporting (reporting bias) Low risk Prespecified outcomes were reported.
Other bias Low risk Funded by government body
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Little 2005a
Methods Randomised controlled trial over 5 years
Participants 807 adults and children aged 3 years and over with cough and at least 1 symptom or sign
localising to the lower respiratory tract were included. Participants were recruited from
37 physicians in England. Of the 807 randomised participants, 272 were randomised to
delayed antibiotics.
Age: for the 272 participants randomised to delayed antibiotics, the average age was 38
years (SD 20); for the 262 participants randomised to immediate antibiotics, it was 40
years (SD 22); and for the 273 participants randomised to no antibiotics, it was 39 years
(SD 20).
Gender: not provided
Exclusion criteria: potential participants were excluded if they were thought to have
pneumonia based on focal chest signs, high fever, vomiting, or diarrhoea. People were
also excluded if they had asthma, chronic or acute lung disease, cystic fibrosis, cardiovas-
cular disease, major psychiatric illness, dementia, or previous complications from lower
respiratory tract infection including a hospital admission for pneumonia
Interventions Participants were randomised to delayed antibiotics (script left at reception and partici-
pants instructed to pick up the script after 14 days if required), immediate antibiotics, or
no antibiotics. Participants in the antibiotic groups were prescribed 250 mg of amoxy-
cillin 3 times a day for 10 days. This dosage was reduced to 125 mg for children aged
less than 10 years. For participants who were penicillin allergic, erythromycin 250 mg 4
times a day was used
Outcomes Primary outcomes: fever, cough, duration of cough, severity of cough, malaise, duration
of malaise, antibiotic use, patient satisfaction
Secondary outcomes: complications of disease, hospital admissions, diarrhoea, recon-
sultation in the 12 months following the index consultation, excluding the first month
after the index consultation
Outcomes were measured using a daily patient diary.
Notes This study was funded by a grant from the UK’s Medical Research Council. The study
authors provided original study data, which we used in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomnumber tables
and block randomisation (block size 6)
Allocation concealment (selection bias) Low risk Opaque, sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Outcome assessor was blinded. Participant
and care provider were not blinded
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Little 2005a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were described, and ITT analy-
sis used.Out of 272 participants randomised
to delayed antibiotics, 214 were included in
the data analysis. Out of 262 participants
randomised to immediate antibiotics, 214
were included in the data analysis. Out of
273 participants randomised to no antibi-
otics, 212 were included in the data analysis.
Selective reporting (reporting bias) Low risk Prespecified outcomes were reported.
Other bias Low risk Funded by government body
Pichichero 1987
Methods Open randomised controlled trial over 27 months
Participants 114 children with sore throat (suspected GABHS) were included who presented to 1
private paediatric practice in New York State, USA. Of these 114 children, 55 were
randomised to delayed antibiotics and 59 were randomised to immediate antibiotics.
Age: of the 55 children randomised to delayed antibiotics, the average age was 7.8 years
(SD 2.3); of the 59 children randomised to immediate antibiotics, it was 7.5 years (SD
2.6).
Gender: not reported
Exclusion criteria included hypersensitivity to penicillin, receipt of antibiotics in pre-
ceding 7 days, acute illness in preceding 7 days, GABHS infection in the preceding
month, and concurrent treatment with an antibiotic other than penicillin
Interventions Children were randomised to delayed antibiotics (48-hour delay) versus immediate an-
tibiotics. Children in each group received penicillin V 250 mg 3 times a day for 10 days
Outcomes Primary outcomes: fever, duration of fever, malaise
Secondary outcomes: reconsultation rates, vomiting
Outcomes were measured using a symptom diary and reassessment at the paediatrician’s
office 3 days after child’s initial enrolment
Notes This studywas funded by the RobertWood Johnson Foundation, Eli Lilly andCompany,
and Elmwood Paediatric Research fund. We approached the authors for their study data,
but they did not provide this information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
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Pichichero 1987 (Continued)
Allocation concealment (selection bias) High risk Allocation concealment measures were not
described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participant and doctor blinded, but there
was no description of outcome assessor
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants dropped out.
Selective reporting (reporting bias) Low risk Prespecified outcomes were reported.
Other bias High risk Funded by philanthropic organisation and
Eli Lilly
Spiro 2006
Methods Placebo and randomised controlled trial over 12 months
Participants 283 children aged 6 months to 12 years were recruited in an emergency department in
Connecticut, USA. 138 of these 283 children were randomised to delayed antibiotics.
Age: for the 138 children randomised to delayed antibiotics, the average age was 3.6
years; for the 145 children randomised to immediate antibiotics, it was 3.2 years.
Gender: 79 of the 138 children in the delayed antibiotics group were male; 76 of the
145 children in the immediate antibiotics group were male.
Exclusion criteria for this study included intercurrent bacterial infection, toxic appear-
ance of child, patient hospitalisation, immunocompromise, child had been treated with
antibiotics in the preceding 7 days, myringotomy tubes, current tympanic membrane
perforation, uncertain medical access, uncertain telephone access, primary language of
guardian other than English or Spanish
Interventions Children were randomised to delayed antibiotics (advised to delay for 48 hours and the
script was to expire after 72 hours) or immediate antibiotics. The clinician chose the
antibiotic.
Outcomes Primary outcome measures: fever, duration of fever, pain, duration of pain, antibiotic
use
Secondary outcome measures: adverse effects of antibiotics including vomiting, diar-
rhoea, and rash
Outcomes were measured by telephone interview by a research assistant with caregivers
of included children
Notes This study was supported by funding from a grant from the US National Institutes of
Health, a grant from the Yale University School of Medicine, and material support from
Friends of Yale-New Haven Children’s Hospital
Risk of bias
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Spiro 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-assisted randomisation
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Study participants were not blinded, but
outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 138 participants randomised to de-
layed antibiotics, outcome data were re-
ported for 132 participants. Of the 145
participants randomised to immediate an-
tibiotics, outcome data were reported for
133 participants. Intention-to-treat analy-
sis was conducted
Selective reporting (reporting bias) Low risk Prespecified outcomes were reported.
Other bias Low risk Funded by government body
AOM: acute otitis media
GABHS: group A beta-haemolytic streptococcus
IQR: interquartile range
ITT: intention-to-treat
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agnew 2013 This study was interested in information leaflets rather than the treatment of respiratory tract infections
with delayed antibiotics versus immediate or no antibiotics.
Cates 1999 Not a randomised controlled trial
De la Poza Abad 2013 Not a randomised controlled trial
Fischer 2009 Not a randomised controlled trial
Little 2014 Not a randomised controlled trial
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(Continued)
Newson 2009 Not a randomised controlled trial
Siegel 2003 Not a randomised controlled trial
Vouloumanou 2009 Not a randomised controlled trial
Worrall 2010 This study was had two delayed antibiotic arms, not immediate versus delayed
Characteristics of ongoing studies [ordered by study ID]
NCT01800747
Trial name or title Clinical Trial for the Assessment of delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics) [Clinical Trial
for the Assessment of delayedAntibiotic Treatment in theNon-complicatedAcute Respiratory Tract Infections
in Pediatric (Study DAP-Pediatrics)]. clinicaltrials.gov/ct2/show/record/NCT01800747 26 February 2013
Methods Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Antibiotic treatment versus delayed antibiotic treatmentMasking: None
(Open Label)
Primary Purpose: Treatment
Participants Children (2 to 14 ages) with non-complicated acute respiratory tract infections, including pharyngotonsillitis,
rhinosinusitis, acute bronchitis and acute media otitis. The doctors include children with these infections if
they have reasonable doubts if they should treat with antibiotics
Interventions Antibiotic prescription strategies
Outcomes Duration and severity of symptoms [ Time Frame: 30 days ]
Starting date June 2012
Contact information Principal Investigator: Pablo Alonso Coello, PhD, Asociación Colaboración Cochrane Iberoamericana
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Pain: delayed versus immediate antibiotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants with
pain on Days 3 to 6
4 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Pain severity on Day 3 2 327 Std. Mean Difference (IV, Fixed, 95% CI) 0.35 [0.13, 0.57]
Comparison 2. Malaise: delayed versus immediate antibiotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of people with malaise
on Day 3
2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Malaise severity on Day 3 2 398 Std. Mean Difference (IV, Fixed, 95% CI) 0.29 [0.09, 0.48]
Comparison 3. Fever: delayed versus immediate antibiotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever on Days 3 to 6 2 394 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.54, 1.38]
2 Fever severity on Day 3 3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 4. Antibiotic use
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Antibiotic use: delayed versus
immediate antibiotics
7 1963 Odds Ratio (M-H, Fixed, 95% CI) 0.04 [0.03, 0.05]
1.1 Antibiotic use: delayed
(prescription at time of visit)
versus immediate antibiotics
3 547 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.06, 0.15]
1.2 Antibiotic use: delayed
(prescription collection) versus
immediate antibiotics
5 1416 Odds Ratio (M-H, Fixed, 95% CI) 0.02 [0.01, 0.03]
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2 Antibiotic use: delayed versus no
antibiotics
4 1241 Odds Ratio (M-H, Random, 95% CI) 2.55 [1.59, 4.08]
2.1 Antibiotic use: delayed
(prescription at time of visit)
versus no antibiotics
2 353 Odds Ratio (M-H, Random, 95% CI) 3.84 [2.18, 6.76]
2.2 Antibiotic use: delayed
(prescription collection) versus
no antibiotics
3 888 Odds Ratio (M-H, Random, 95% CI) 2.05 [1.11, 3.80]
Comparison 5. Patient satisfaction
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patient satisfaction: delayed
versus immediate antibiotics
6 1633 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.39, 1.10]
2 Patient satisfaction: delayed
versus no antibiotics
4 1235 Odds Ratio (M-H, Random, 95% CI) 1.49 [1.08, 2.06]
Comparison 6. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vomiting: delayed versus
immediate antibiotics
3 Odds Ratio (M-H, Random, 95% CI) Totals not selected
2 Diarrhoea: delayed versus
immediate antibiotics
4 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Rash: delayed versus immediate
antibiotics
2 680 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.54, 1.97]
Comparison 7. Reconsultation rate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reconsultation rate: delayed
versus immediate antibiotics
2 379 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.55, 1.98]
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Analysis 1.1. Comparison 1 Pain: delayed versus immediate antibiotics, Outcome 1 Number of participants
with pain on Days 3 to 6.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 1 Pain: delayed versus immediate antibiotics
Outcome: 1 Number of participants with pain on Days 3 to 6
Study or subgroup Delayed antibiotics
Immediate
antibiotics Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arroll 2002a 13/61 9/58 1.47 [ 0.58, 3.77 ]
El-Daher 1991 106/118 42/111 14.51 [ 7.14, 29.50 ]
Little 2001 28/111 15/101 1.93 [ 0.96, 3.88 ]
Spiro 2006 85/132 89/133 0.89 [ 0.54, 1.48 ]
0.01 0.1 1 10 100
Favours delay Favours immediate
Analysis 1.2. Comparison 1 Pain: delayed versus immediate antibiotics, Outcome 2 Pain severity on Day 3.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 1 Pain: delayed versus immediate antibiotics
Outcome: 2 Pain severity on Day 3
Study or subgroup Delayed antibiotics
Immediate
antibiotics
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Little 2001 111 2.56 (2.14) 102 1.81 (1.44) 64.8 % 0.41 [ 0.13, 0.68 ]
Pichichero 1987 55 1.6 (1.38) 59 1.3 (1) 35.2 % 0.25 [ -0.12, 0.62 ]
Total (95% CI) 166 161 100.0 % 0.35 [ 0.13, 0.57 ]
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 3.15 (P = 0.0017)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours delay Favours immediate
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Analysis 2.1. Comparison 2 Malaise: delayed versus immediate antibiotics, Outcome 1 Number of people
with malaise on Day 3.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 2 Malaise: delayed versus immediate antibiotics
Outcome: 1 Number of people with malaise on Day 3
Study or subgroup Delay Immediate Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Daher 1991 45/118 4/111 16.49 [ 5.68, 47.83 ]
Little 2001 45/150 19/135 2.62 [ 1.44, 4.76 ]
0.01 0.1 1 10 100
Favours delay Favours immediate
Analysis 2.2. Comparison 2 Malaise: delayed versus immediate antibiotics, Outcome 2 Malaise severity on
Day 3.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 2 Malaise: delayed versus immediate antibiotics
Outcome: 2 Malaise severity on Day 3
Study or subgroup Delay Immediate
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Little 2001 150 0.83 (1.69) 134 0.4 (0.97) 71.2 % 0.31 [ 0.07, 0.54 ]
Pichichero 1987 55 1.3 (1) 59 1.1 (0.67) 28.8 % 0.24 [ -0.13, 0.60 ]
Total (95% CI) 205 193 100.0 % 0.29 [ 0.09, 0.48 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours delay Favours immediate
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Analysis 3.1. Comparison 3 Fever: delayed versus immediate antibiotics, Outcome 1 Fever on Days 3 to 6.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 3 Fever: delayed versus immediate antibiotics
Outcome: 1 Fever on Days 3 to 6
Study or subgroup Delay Immediate Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arroll 2002a 5/67 6/62 15.6 % 0.75 [ 0.22, 2.60 ]
Spiro 2006 42/132 46/133 84.4 % 0.88 [ 0.53, 1.47 ]
Total (95% CI) 199 195 100.0 % 0.86 [ 0.54, 1.38 ]
Total events: 47 (Delay), 52 (Immediate)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delay Favours immediate
Analysis 3.2. Comparison 3 Fever: delayed versus immediate antibiotics, Outcome 2 Fever severity on Day
3.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 3 Fever: delayed versus immediate antibiotics
Outcome: 2 Fever severity on Day 3
Study or subgroup Delay Immediate
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Arroll 2002a 61 36.15 (0.73) 58 36.39 (0.58) -0.24 [ -0.48, 0.00 ]
Pichichero 1987 55 37.2 (1.17) 59 36.8 (0.61) 0.40 [ 0.05, 0.75 ]
El-Daher 1991 118 38 (1.96) 111 37.1 (0.95) 0.90 [ 0.50, 1.30 ]
-10 -5 0 5 10
Favours delay Favours immediate
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Analysis 4.1. Comparison 4 Antibiotic use, Outcome 1 Antibiotic use: delayed versus immediate antibiotics.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 4 Antibiotic use
Outcome: 1 Antibiotic use: delayed versus immediate antibiotics
Study or subgroup Delayed Immediate Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotic use: delayed (prescription at time of visit) versus immediate antibiotics
Arroll 2002a 32/67 55/67 4.6 % 0.20 [ 0.09, 0.44 ]
De la Poza Abad 2016 32/98 46/50 6.6 % 0.04 [ 0.01, 0.13 ]
Spiro 2006 50/132 116/133 11.6 % 0.09 [ 0.05, 0.17 ]
Subtotal (95% CI) 297 250 22.8 % 0.10 [ 0.06, 0.15 ]
Total events: 114 (Delayed), 217 (Immediate)
Heterogeneity: Chi2 = 5.45, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 10.41 (P < 0.00001)
2 Antibiotic use: delayed (prescription collection) versus immediate antibiotics
De la Poza Abad 2016 23/100 46/51 7.6 % 0.03 [ 0.01, 0.09 ]
Dowell 2001 43/95 92/92 8.3 % 0.00 [ 0.00, 0.07 ]
Little 1997 55/176 210/211 21.1 % 0.00 [ 0.00, 0.02 ]
Little 2001 36/150 132/151 16.1 % 0.05 [ 0.02, 0.08 ]
Little 2005a 39/197 185/193 24.1 % 0.01 [ 0.00, 0.02 ]
Subtotal (95% CI) 718 698 77.2 % 0.02 [ 0.01, 0.03 ]
Total events: 196 (Delayed), 665 (Immediate)
Heterogeneity: Chi2 = 17.77, df = 4 (P = 0.001); I2 =77%
Test for overall effect: Z = 19.46 (P < 0.00001)
Total (95% CI) 1015 948 100.0 % 0.04 [ 0.03, 0.05 ]
Total events: 310 (Delayed), 882 (Immediate)
Heterogeneity: Chi2 = 46.33, df = 7 (P<0.00001); I2 =85%
Test for overall effect: Z = 22.62 (P < 0.00001)
Test for subgroup differences: Chi2 = 32.68, df = 1 (P = 0.00), I2 =97%
0.001 0.01 0.1 1 10 100 1000
Delayed antibiotics Immediate antibiotics
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Analysis 4.2. Comparison 4 Antibiotic use, Outcome 2 Antibiotic use: delayed versus no antibiotics.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 4 Antibiotic use
Outcome: 2 Antibiotic use: delayed versus no antibiotics
Study or subgroup Delayed No Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Antibiotic use: delayed (prescription at time of visit) versus no antibiotics
Chao 2008 40/106 13/100 20.4 % 4.06 [ 2.01, 8.19 ]
De la Poza Abad 2016 32/98 6/49 14.7 % 3.47 [ 1.34, 9.01 ]
Subtotal (95% CI) 204 149 35.1 % 3.84 [ 2.18, 6.76 ]
Total events: 72 (Delayed), 19 (No)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 4.66 (P < 0.00001)
2 Antibiotic use: delayed (prescription collection) versus no antibiotics
De la Poza Abad 2016 23/100 6/49 14.4 % 2.14 [ 0.81, 5.66 ]
Little 1997 55/176 23/184 25.1 % 3.18 [ 1.85, 5.46 ]
Little 2005a 39/197 29/182 25.4 % 1.30 [ 0.77, 2.21 ]
Subtotal (95% CI) 473 415 64.9 % 2.05 [ 1.11, 3.80 ]
Total events: 117 (Delayed), 58 (No)
Heterogeneity: Tau2 = 0.18; Chi2 = 5.37, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 2.30 (P = 0.021)
Total (95% CI) 677 564 100.0 % 2.55 [ 1.59, 4.08 ]
Total events: 189 (Delayed), 77 (No)
Heterogeneity: Tau2 = 0.15; Chi2 = 8.94, df = 4 (P = 0.06); I2 =55%
Test for overall effect: Z = 3.91 (P = 0.000094)
Test for subgroup differences: Chi2 = 2.16, df = 1 (P = 0.14), I2 =54%
0.1 0.2 0.5 1 2 5 10
Delayed antibiotics No antibiotics
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Analysis 5.1. Comparison 5 Patient satisfaction, Outcome 1 Patient satisfaction: delayed versus immediate
antibiotics.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 5 Patient satisfaction
Outcome: 1 Patient satisfaction: delayed versus immediate antibiotics
Study or subgroup Delayed antibiotic Immediate antibiotic Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Arroll 2002a 64/67 58/62 8.6 % 1.47 [ 0.32, 6.85 ]
De la Poza Abad 2016 170/198 83/101 23.1 % 1.32 [ 0.69, 2.52 ]
Dowell 2001 71/73 75/75 2.7 % 0.19 [ 0.01, 4.01 ]
Little 1997 165/177 202/211 17.5 % 0.61 [ 0.25, 1.49 ]
Little 2001 115/150 123/135 21.7 % 0.32 [ 0.16, 0.65 ]
Little 2005a 147/190 166/194 26.4 % 0.58 [ 0.34, 0.97 ]
Total (95% CI) 855 778 100.0 % 0.65 [ 0.39, 1.10 ]
Total events: 732 (Delayed antibiotic), 707 (Immediate antibiotic)
Heterogeneity: Tau2 = 0.19; Chi2 = 10.39, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours immediate Favours delay
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Analysis 5.2. Comparison 5 Patient satisfaction, Outcome 2 Patient satisfaction: delayed versus no
antibiotics.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 5 Patient satisfaction
Outcome: 2 Patient satisfaction: delayed versus no antibiotics
Study or subgroup Delayed antibiotics No antibiotics Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chao 2008 101/106 91/100 8.2 % 2.00 [ 0.65, 6.18 ]
De la Poza Abad 2016 170/198 78/99 26.6 % 1.63 [ 0.87, 3.06 ]
Little 1997 165/177 166/184 18.0 % 1.49 [ 0.70, 3.19 ]
Little 2005a 147/190 130/181 47.3 % 1.34 [ 0.84, 2.14 ]
Total (95% CI) 671 564 100.0 % 1.49 [ 1.08, 2.06 ]
Total events: 583 (Delayed antibiotics), 465 (No antibiotics)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours no antibiotics Favours delay
Analysis 6.1. Comparison 6 Adverse events, Outcome 1 Vomiting: delayed versus immediate antibiotics.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 6 Adverse events
Outcome: 1 Vomiting: delayed versus immediate antibiotics
Study or subgroup Delayed antibiotics
Immediate
antibiotics Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
El-Daher 1991 57/118 4/111 25.00 [ 8.65, 72.25 ]
Little 1997 15/179 18/215 1.00 [ 0.49, 2.05 ]
Spiro 2006 15/132 15/133 1.01 [ 0.47, 2.16 ]
0.001 0.01 0.1 1 10 100 1000
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Analysis 6.2. Comparison 6 Adverse events, Outcome 2 Diarrhoea: delayed versus immediate antibiotics.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 6 Adverse events
Outcome: 2 Diarrhoea: delayed versus immediate antibiotics
Study or subgroup Delayed antibiotics
Immediate
antibiotics Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arroll 2002a 11/67 12/62 0.82 [ 0.33, 2.02 ]
Little 1997 23/179 23/215 1.23 [ 0.67, 2.28 ]
Little 2001 14/150 25/135 0.45 [ 0.22, 0.91 ]
Spiro 2006 10/132 31/133 0.27 [ 0.13, 0.58 ]
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Analysis 6.3. Comparison 6 Adverse events, Outcome 3 Rash: delayed versus immediate antibiotics.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 6 Adverse events
Outcome: 3 Rash: delayed versus immediate antibiotics
Study or subgroup Delayed antibiotics
Immediate
antibiotics Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Little 1997 11/180 14/215 66.7 % 0.93 [ 0.41, 2.11 ]
Little 2001 8/150 6/135 33.3 % 1.21 [ 0.41, 3.58 ]
Total (95% CI) 330 350 100.0 % 1.03 [ 0.54, 1.97 ]
Total events: 19 (Delayed antibiotics), 20 (Immediate antibiotics)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Delayed antibiotics Favours Immediate antibiotics
Analysis 7.1. Comparison 7 Reconsultation rate, Outcome 1 Reconsultation rate: delayed versus immediate
antibiotics.
Review: Delayed antibiotic prescriptions for respiratory infections
Comparison: 7 Reconsultation rate
Outcome: 1 Reconsultation rate: delayed versus immediate antibiotics
Study or subgroup Delayed antibiotics
Immediate
antibiotics Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pichichero 1987 8/55 10/59 45.5 % 0.83 [ 0.30, 2.29 ]
Spiro 2006 13/132 11/133 54.5 % 1.21 [ 0.52, 2.81 ]
Total (95% CI) 187 192 100.0 % 1.04 [ 0.55, 1.98 ]
Total events: 21 (Delayed antibiotics), 21 (Immediate antibiotics)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Delayed antibiotics Favours Immediate antibiotics
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A D D I T I O N A L T A B L E S
Table 1. TIDieR (Template for Intervention Description and Replication) table
Author
Year
Disease Partici-
pants
Trial
out-
comes
Materi-
als and
proce-
dures
for
clini-
cians
deliver-
ing in-
terven-
tion
Clini-
cians
deliver-
ing in-
terven-
tion
How
inter-
vention
was de-
liv-
ered to
partici-
pants
Where
inter-
vention
was de-
livered
When
and
how
much
Tailor-
ing
Modi-
fied
during
trial?
Checks
of fi-
delity?
Fi-
delity
Arroll
2002a
Com-
mon
cold
Any age Antibi-
otic use,
satisfac-
tion,
and
symp-
toms of
delayed
pre-
scribing
An-
tibiotic
pre-
scrip-
tion
(deemed
appro-
priate
by
treating
GP).
Proce-
dure
not de-
tailed
15 GPs De-
layed: to
fill pre-
scrip-
tion af-
ter
3 days
if symp-
toms
not im-
proved
Imme-
diate:
usual
care
1 gen-
eral
prac-
tice,
New
Zealand
Once,
at index
consul-
tation;
delayed
group
asked to
wait 3
days
Partici-
pants
ad-
vised to
return
to GP if
symp-
toms
wors-
ened.
None
re-
ported
Not de-
tailed
-
Chao
2008
Acute
otitis
media
Chil-
dren
(2 to 12
years)
Antibi-
otic use
2 forms
of dis-
charge
instruc-
tion
sheet
pro-
vided
by clini-
cians to
pa-
tients:
1) com-
pletion
14
emer-
gency
depart-
ment
physi-
cians
Not de-
tailed
Emer-
gency
depart-
ment of
an
urban
pub-
lic hos-
pital in
the
USA
Once,
at index
consul-
tation
Pro-
vided
with
compli-
men-
tary op-
tional
ibupro-
fen or
parac-
etamol
+/- ben-
zocaine
None
re-
ported
None None
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Table 1. TIDieR (Template for Intervention Description and Replication) table (Continued)
of all:
when to
re-
turn for
medical
care (af-
ter 2 to
3 days)
; how to
use
compli-
men-
tary
symp-
tom
drugs
2) com-
par-
ison: as
above +
pre-
scrip-
tion
to fill if
still un-
well at
2 to 3
days
otic
drops
at index
consul-
tation
De
la Poza
Abad
2016
Acute
uncom-
plicated
respira-
tory in-
fection
Adults Symp-
tomdu-
ration
and
severity,
antibi-
otic use,
patient
satisfac-
tion,
pa-
tients’
be-
liefs in
antibi-
otic ef-
fective-
ness
Physi-
cian
struc-
tured
script
and
patient
infor-
mation
sheet
about
self lim-
iting
natural
history
of respi-
ratory
infec-
tion,
GPs 4
groups
of an-
tibiotic
pre-
scrip-
tion
use:
1) im-
medi-
ate;
2)
delayed,
patient-
led pre-
scrip-
tion;
3)
delayed,
23 pri-
mary
care
cen-
tres in 4
regions
in Spain
Once,
at index
consul-
tation;
delayed
pre-
scrip-
tion
collec-
tion
group
could
collect
after 3
days if
needed
All ad-
vised to
return
if no
im-
prove-
ment or
wors-
ening
after 5
days
(pharyn-
gitis) or
10 days
(other
infec-
tions)
Central
None
re-
ported
None None
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Table 1. TIDieR (Template for Intervention Description and Replication) table (Continued)
pros
and
cons of
antibi-
otics
used
with
patients
Antibi-
otic
pre-
scrip-
tion
as indi-
cated
pre-
scrip-
tion
collec-
tion;
4)
none.
Delayed
= 3 days
phone
follow-
up
if symp-
toms
per-
sisted
Dowell
2001
Acute
uncom-
plicated
cough
Adults
(> 16
years)
Symp-
tomdu-
ration,
pre-
scrip-
tion
uptake,
patient
satis-
faction,
patient
enable-
ment
subse-
quent
consul-
tation
rates
Antibi-
otic
pre-
scrip-
tion
of GP’s
choice
pro-
vided or
lodged
at re-
ception
48 GPs Imme-
diate:
usual
care
delayed:
col-
lect pre-
scrip-
tion af-
ter 1
week if
re-
quired
(within
2
weeks)
22 gen-
eral
prac-
tices in
Scot-
land,
UK
Once,
at index
consul-
tation;
delayed
pre-
scrip-
tion
group
asked to
wait 1
week
Nil None
re-
ported
Date
scripts
col-
lected
by
delayed
group
35%
(12/34)
waited
7
days as
asked;
mean
wait
6 days
(range 1
to 10)
El-
Daher
1991
GABHS
Chil-
dren
(4 to 14
years)
Signs
and
symp-
toms,
anti-
body
titre,
subse-
quent
episodes
Imme-
diate
group:
sup-
plied
with 2
days
of peni-
cillin,
then 8
days
of peni-
cillin
on Day
Physi-
cian
Imme-
diate:
2 days
peni-
cillin,
then
8 days
peni-
cillin
delayed:
2 days
placebo,
then
Paedi-
atric
clinics
at Jor-
dan
Univer-
sity of
Science
and
Tech-
nology,
Jordan
At
index
consul-
tation,
then re-
exam-
ined on
Day 3
Parac-
eta-
mol as
needed
None
re-
ported
None
re-
ported
None
re-
ported
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Table 1. TIDieR (Template for Intervention Description and Replication) table (Continued)
3
delayed
group:
sup-
plied
with 2
days of
placebo,
then 10
days of
peni-
cillin
on Day
3
10 days
peni-
cillin
Gerber
1990 GABHS
pharyn-
gitis
Chil-
dren /
adoles-
cents
(2 to 22
years)
Positive
follow-
up
throat
cul-
tures,
recur-
rences,
symp-
tomatic
recur-
rences,
or new
acquisi-
tions
Imme-
diate
group:
sup-
plied
with
10-day
course
of dose
appro-
priate
peni-
cillin V
Delayed
group:
in-
structed
to wait
48
hours
before
com-
menc-
ing 10-
day
course
of peni-
cillin
Tele-
phone
follow-
up 24
Not re-
ported
(im-
plied
treating
physi-
cians)
Imme-
diate:
usual
care
delayed:
wait 48
hours
before
com-
menc-
ing
peni-
cillin
1
private
paedi-
atric
practice
in the
USA
At
index
consul-
tation
and
tele-
phone
follow-
up 24
and 48
hours
after-
wards
Further
10-day
courses
of peni-
cillin if
further
GABHS
pharyn-
gitis
None
re-
ported
Urine
sample
at
Day 9,
mailed
af-
ter dry-
ing for
analysis
No re-
port
of urine
sample
compli-
ance re-
sults
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Table 1. TIDieR (Template for Intervention Description and Replication) table (Continued)
hours
later in
both
groups
and
next 24
hours
for
delayed
group
to
advise
com-
mence-
ment
Little
1997
Sore
throat
≥ 4
years
Dura-
tion of
symp-
toms,
satisfac-
tion
and
compli-
ance
with
and
per-
ceived
ef-
ficacy of
antibi-
otics,
time off
school
or work
Imme-
diate
group
given
10-
day pre-
scrip-
tion
of dose
appro-
priate
peni-
cillin V
Delayed
group
offered
antibi-
otics
but
could
collect
pre-
scrip-
tion if
symp-
toms
not
settled
within
3 days
GP
stan-
25 GPs 3
groups
of an-
tibiotic
pre-
scrip-
tions:
1) im-
medi-
ate:
usual
care;
2) no
antibi-
otics;
3) de-
layed: to
collect
within
3 days.
11 gen-
eral
prac-
tices,
Eng-
land,
UK
At
index
consul-
tation;
delayed
pre-
scrip-
tion
group
within
3 days
Ery-
thromycin
if sensi-
tive to
peni-
cillin.
Anal-
gesics
or an-
tipyret-
ics al-
lowed.
None
re-
ported
GP
docu-
mented
pre-
scrip-
tion on
sheet.
Patient
daily
diary
until
symp-
tom-
free and
medica-
tion
finished
GPs’
compli-
ance:
imme-
diate:
99%;
no ABs:
2%; de-
layed:
5% left
with
script
AB use:
imme-
diate:
99%;
no:
13%;
delayed:
31%
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Table 1. TIDieR (Template for Intervention Description and Replication) table (Continued)
dard
advice
sheets
pro-
vided to
partici-
pants
Little
2001
Acute
otitis
media
Chil-
dren (0.
5 to 10
years)
Symp-
tom
resolu-
tion,
absence
from
school
or nurs-
ery,
parac-
etamol
con-
sump-
tion
Imme-
diate
group
pre-
scribed
amoxi-
cillin.
Delayed
group
asked to
delay 3
days be-
fore us-
ing pre-
scrip-
tion,
and
then
only
if neces-
sary
GP
used
stan-
dard-
ised ad-
vice
sheets
specific
to each
group
42 GPs Imme-
diate:
usual
care
delayed:
wait
3 days
to col-
lect pre-
scrip-
tion
General
prac-
tices
in Scot-
land,
UK
At
index
consul-
tation;
delayed
pre-
scrip-
tion
group
asked to
wait 3
days
An-
tipyret-
ics were
al-
lowed.
None
re-
ported
Patient
diary
No
Little
2005a
Acute
uncom-
plicated
lower
respira-
tory
tract in-
fection
≥ 3
years
Symp-
tomdu-
ration
and
severity,
antibi-
otic use,
satisfac-
tion,
Imme-
diate
group:
pre-
scrip-
tion for
10 days
amoxi-
cillin.
37 GPs 6
groups
(facto-
rial):
1) no
antibi-
otics,
no
leaflet;
General
prac-
tices,
Eng-
land,
UK
At
index
consul-
ta-
tion; 14
days for
delayed
pre-
Ery-
thromycin
if aller-
gic to
peni-
cillin.
An-
tipyret-
None
re-
ported
Re-
ported
antibi-
otic use
in diary
96%
imme-
diate
group;
20%
delayed
group;
16% no
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Table 1. TIDieR (Template for Intervention Description and Replication) table (Continued)
belief in
antibi-
otics
Delayed
group:
pre-
scrip-
tion
written
and left
at re-
ception
for pa-
tient to
re-
trieve if
wanted
(but ad-
vised to
wait 14
days)
Leaflet
groups:
1-page
infor-
mation
leaflet
cover-
ing nat-
ural his-
tory of
illness,
when to
seek
further
help
All
groups:
state-
ment
about
anal-
gesics,
natural
history
of
illness,
and
pre-
2)
delayed
antibi-
otics,
no
leaflet;
3) im-
mediate
antibi-
otics,
no
leaflet;
4) no
antibi-
otics,
leaflet;
5)
delayed
antibi-
otics
and
leaflet;
6) im-
mediate
antibi-
otics
and
leaflet.
Delay =
14 days
scrip-
tion
group
ics
allowed
ABs
group
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Table 1. TIDieR (Template for Intervention Description and Replication) table (Continued)
scribing
strategy
read
out by
physi-
cians
Pichichero
1987
Sore
throat
(pre-
sumed
GABHS)
Chil-
dren
(4 to 18
years)
Symp-
tomatic
re-
sponse,
recur-
rent in-
fections
Drugs
sup-
plied
directly
to pa-
tients.
Usual
care 10-
day
course
peni-
cillin V.
Delayed
group
pro-
vided
with
placebo
for first
3 days,
then
peni-
cillin
Study
nurse
Imme-
diate:
usual
care
delayed:
placebo
for
3 days
then
peni-
cillin
Pri-
mary
care
paedi-
atric
practice
in the
USA
At
index
consul-
tation
Antibi-
otic
(tablet
or sus-
pen-
sion).
An-
tipyret-
ics were
allowed
None
re-
ported
Check
drug
bot-
tles at 3
days
and 3
weeks.
Test
urine at
3 days
for an-
tibiotic
Con-
firmed
in 98%
cases
(drug
bot-
tles); no
ABs
used in
placebo
group
Spiro
2006
Acute
otitis
media
Chil-
dren (0.
5 to 12
years)
Antibi-
otic use,
clinical
symp-
toms,
adverse
out-
comes,
days off
school
or
work,
un-
sched-
uled
medical
visits,
parents’
Provi-
sion
of writ-
ten pre-
scrip-
tion for
antibi-
otics
valid
for 3
days
Wait-
and-
see pre-
scrip-
tion
group
given
Emer-
gency
depart-
ment
clini-
cians
Imme-
diate:
usual
care
Wait-
and-
see pre-
scrip-
tion:
wait 2
days
Paedi-
atric
emer-
gency
depart-
ment
in the
USA
At
index
consul-
tation
and
within
3 days if
pre-
scrip-
tion
filled
Ibupro-
fen
and otic
drops as
needed.
Pri-
mary
care
contact
if wors-
ening
None
re-
ported
Verifi-
ca-
tion of
filling
of pre-
scrip-
tion by
phone
call
to des-
ignated
phar-
ma-
cies for
28% of
the
All in-
stances
of no
filling
of pre-
scrip-
tion
con-
firmed
by
phar-
macies,
and
90%
confir-
mation
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Table 1. TIDieR (Template for Intervention Description and Replication) table (Continued)
com-
fort
with
man-
age-
ment
written
and
verbal
instruc-
tions
to only
fill pre-
scrip-
tion if
no im-
prove-
ment or
wors-
ening
2 days
after
emer-
gency
room
visit
sample of
parent
report
of pre-
scrip-
tion
filled
ABs: antibiotics
GABHS: group A beta-haemolytic streptococcus
GP: general practitioner
Table 2. Summary of clinical outcomes: delayed versus immediate antibiotics
Study Outcome Delay Immediate Favours Result (95% CI)
Sore throat
Pichichero 1987 Fever severity on
Day 3
37.2 (SD 1.2, n =
55)
36.8 (SD 0.6, n =
59)
Immediate
antibiotics
MD 0.40 (95% CI
0.05 to 0.75)
Malaise severity on
Day 3
1.3 (SD 1.0, n = 55) 1.1 (SD 0.7, n = 59) No difference MD 0.20 (95%CI -
0.11 to 0.51)
Pain severity onDay
3
1.6 (SD 1.4, n = 55) 1.3 (SD 1.3, n = 59) No difference MD 0.30 (95%CI -
0.15 to 0.75)
Compliance 55/55 59/59 No difference 100% in both
groups
Gerber 1990 Recurrence rate - - No difference Data not available
Compliance 44/50 59/63 Delayed antibiotics 88% in immediate
group and 93% in
delayed group
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Table 2. Summary of clinical outcomes: delayed versus immediate antibiotics (Continued)
El-Daher 1991 Vomiting 57/118 4/111 Immediate
antibiotics
OR 25.00 (95% CI
8.65 to 72.25)
Pain on Day 3 106/118 42/111 Immediate
antibiotics
OR 14.51 (95% CI
7.14 to 29.50)
Malaise on Day 3 45/118 4/111 Immediate
antibiotics
OR 16.49 (95% CI
5.68 to 47.83)
Fever severity on
Day 3
38.0 °C (SD 2.0, n
= 118)
37.1 °C (SD 1.0, n
= 111)
Immediate
antibiotics
SMD 0.58 (95%CI
0.31 to 0.84)
Little 1997 Vomiting 15/179 18/215 No difference OR1.00 (95%CI0.
49 to 2.05)
Diarrhoea 23/179 23/215 No difference OR1.23 (95%CI0.
67 to 2.28)
Rash 11/180 14/215 No difference OR0.93 (95%CI0.
41 to 2.11)
Stomachache 48/180 66/215 No difference OR0.82 (95%CI0.
53 to 1.27)
Fever (> 37.0 °C) Unavailable Unavailable Immediate
antibiotics
Data not available
Pain Unavailable Unavailable No difference Data not available
Cough Unavailable Unavailable No difference Data not available
Malaise Unavailable Unavailable No difference Data not available
Analgesic use Unavailable Unavailable No difference Data not available
Time off work Unavailable Unavailable No difference Data not available
De la Poza Abad
2016
Pain duration (de-
layed prescription at
time of visit)
5.7 days (SD 5.1, n
= 45)
4.4 days (SD 2.4, n
= 47)
No difference MD 1.30 (95%CI -
0.34 to 2.94)
Pain duration (de-
layed
prescription requir-
ing collection)
7.4 days (SD 6.3, n
= 46)
4.4 days (SD 2.4, n
= 47)
Immediate
antibiotics
MD 3.00 (95%CI -
1.03 to 4.95)
Fever duration (de-
layed prescription at
time of visit)
3.1 days (SD 1.8, n
= 45)
2.9 days (SD 1.7, n
= 47)
No difference MD -0.20 (95% CI
-0.52 to 0.92)
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Table 2. Summary of clinical outcomes: delayed versus immediate antibiotics (Continued)
Fever duration (de-
layed
prescription requir-
ing collection)
3.4 days (SD 2.4, n
= 46)
2.9 days (SD 1.7, n
= 47)
No difference MD 0.50 (95%CI -
0.35 to 1.35)
Cough du-
ration (delayed pre-
scription at time of
visit)
8.1 days (SD 5.9, n
= 45)
8.1 days (SD 5.7, n
= 47)
No difference MD -2.50 (95% CI
-5.52 to 0.52)
Cough du-
ration (delayed pre-
scription requiring
collection)
8.2 days (SD 6.9, n
= 46)
8.1 days (SD 5.7, n
= 47)
No difference MD -2.40 (95% CI
-5.59 to 0.79)
Nasal mucosity du-
ration (delayed pre-
scription at time of
visit)
7.2 days (SD 4.3, n
= 45)
5.4 days (SD 3.9, n
= 47)
Immediate
antibiotics
MD -1.80 (95% CI
0.12 to 3.48)
Nasal mucosity du-
ration (delayed pre-
scription requiring
collection)
9.7 days (SD 8.3, n
= 46)
8.9 days (SD 6.5, n
= 46)
Immediate
antibiotics
MD 4.30 (95% CI
1.65 to 6.95)
Acute otitis media
Little 2001 Diarrhoea 14/150 25/135 Delayed antibiotics OR0.45 (95%CI0.
22 to 0.91)
Rash 8/150 6/135 No difference OR1.21 (95%CI0.
41 to 2.58)
Participants with
pain on Day 3
28/111 15/101 No difference OR1.93 (95%CI0.
96 to 3.88)
Participants with
pain on Day 7
3/111 0/101 No difference OR6.55 (95%CI0.
33 to 128.35)
Participants with
malaise on Day 3
45/150 19/135 Immediate
antibiotics
OR2.62 (95%CI1.
44 to 4.76)
Malaise severityDay
3
0.8 (SD 1.7, n =
150)
0.4 (SD 1.0, n =
134)
Immediate
antibiotics
MD 0.43 (95% CI
0.11 to 0.75)
Malaise severity on
Day 7
2.2 (SD 2.0, n =
150)
1.5 (SD 1.2, n =
135)
No difference MD 0.01 (95%CI -
0.11 to 0.13)
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Table 2. Summary of clinical outcomes: delayed versus immediate antibiotics (Continued)
Pain severity onDay
3
2.6 (SD 2.1, n =
111)
1.8 (SD 1.4, n =
102)
Immediate
antibiotics
MD 0.75 (95% CI
0.26 to 1.24)
Pain severity onDay
7
1.17 (SD 0.75, n =
111)
1.05 (SD 0.38, n =
101)
No difference MD 0.12 (95%CI -
0.04 to 0.28)
Paracetamol
consumption
2.3 spoons 1.7 spoons Immediate
antibiotics
MD 0.59 (95% CI
0.25 to 0.93)
Last day of crying 2.2 days 1.5 days Immediate
antibiotics
MD 0.69 (95% CI
0.31 to 1.07)
Little 2006 Episodes of earache
in the 3 months
since randomisation
Unavailable Unavailable No difference OR0.89 (95%CI0.
48 to 1.65)
Episodes of earache
over 1 year
Unavailable Unavailable No difference OR1.03 (95%CI0.
60 to 1.78)
Spiro 2006 Pain day 4 to 6 85/132 89/133 No difference OR0.89 (95%CI0.
54 to 1.48)
Fever day 4 to 6 42/132 46/133 No difference OR0.88 (95%CI0.
53 to 1.47)
Vomiting 15/132 15/133 No difference OR1.01 (95%CI0.
47 to 2.16)
Diarrhoea 10/132 31/133 Delayed antibiotics OR0.27 (95%CI0.
13 to 0.58)
Cough
Dowell 2001 Clinical outcomes Unavailable Unavailable No difference Data not available
Little 2005a Clinical outcomes Unavailable Unavailable No difference Data not available
De la Poza Abad
2016
Pain duration (de-
layed prescription at
time of visit)
11.0 days (SD8.0, n
= 32)
10.5 days (SD 8.0, n
= 32)
No difference MD 0.50 (95%CI -
0.34 to 4.42)
Pain duration (de-
layed
prescription requir-
ing collection)
8.9 days (SD 6.9, n
= 32)
10.5 days (SD 8.0, n
= 32)
No difference MD -1.60 (95% CI
-5.26 to 2.06)
Fever duration (de-
layed prescription at
time of visit)
5.6 days (SD 5.9, n
= 32)
4.1 days (SD 5.7, n
= 32)
No difference MD 1.50 (95%CI -
1.34 to 4.34)
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Table 2. Summary of clinical outcomes: delayed versus immediate antibiotics (Continued)
Fever duration (de-
layed
prescription requir-
ing collection)
4.7 days (SD 4.6, n
= 32)
4.1 days (SD 5.7, n
= 32)
No difference MD 0.60 (95%CI -
1.94 to 3.14)
Cough du-
ration (delayed pre-
scription at time of
visit)
15.6 days (SD8.8, n
= 32)
13.0 days (SD 7.0, n
= 32)
No difference MD 2.60 (95%CI -
1.30 to 6.50)
Cough du-
ration (delayed pre-
scription requiring
collection)
12 days (SD 5.6, n =
32)
13.0 days (SD 7.0, n
= 32)
No difference MD -1.00 (95% CI
-4.11 to 2.11)
Common cold
Arroll 2002a Participants with
fever on Day 3
5/67 6/62 No difference OR0.75 (95%CI0.
22 to 2.6)
Participants with
fever on Day 7
3/67 4/62 No difference OR0.68 (95%CI0.
15 to 3.17)
Participants with di-
arrhoea
11/67 12/62 No difference OR0.79 (95%CI0.
53 to 1.19)
Participants with
pain on Day 3
13/61 9/58 No difference OR1.47 (95%CI0.
58 to 3.77)
Participants with
pain on Day 7
1/61 3/58 No difference OR0.31 (95%CI0.
03 to 3.03)
Participants with
cough on Day 3
54/67 51/62 No difference OR0.90 (95%CI0.
37 to 2.18)
Participants with
cough on Day 7
41/61 43/58 No difference OR0.72 (95%CI0.
32 to 1.58)
Fever severity on
Day 3
36.2 °C (SD 0.7, n
= 61)
36.4 °C (SD 0.6, n
= 58)
No difference MD -0.24 (95% CI
-0.48 to 0.00)
Fever severity on
Day 7
36.0 °C (SD 0.8, n
= 59)
36.3 °C (SD 0.6, n
= 60)
Delayed antibiotics MD -0.32 (95% CI
-0.57 to -0.07)
De la Poza Abad
2016
Pain duration (de-
layed prescription at
time of visit)
8.4 days (SD 8.2, n
= 29)
6.7 days (SD 4.5, n
= 20)
No difference MD 1.70 (95%CI -
1.88 to 5.28)
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Table 2. Summary of clinical outcomes: delayed versus immediate antibiotics (Continued)
Pain duration (de-
layed
prescription requir-
ing collection)
10.1 days (SD7.5, n
= 20)
6.7 days (SD 4.5, n
= 20)
No difference MD 3.40 (95%CI -
0.43 to 7.23)
Fever duration (de-
layed prescription at
time of visit)
3.0 days (SD 1.2, n
= 29)
5.3 days (SD 6.2, n
= 20)
No difference MD -2.30 (95% CI
-5.05 to 0.45)
Fever duration (de-
layed
prescription requir-
ing collection)
4.2 days (SD 3.0, n
= 20)
5.3 days (SD 6.2, n
= 20)
No difference MD -1.10 (95% CI
-4.12 to 1.92)
Cough du-
ration (delayed pre-
scription at time of
visit)
8.3 days (SD 5.2, n
= 29)
7.6 days (SD 5.6, n
= 20)
No difference MD -0.70 (95% CI
-2.40 to 3.80)
Cough du-
ration (delayed pre-
scription requiring
collection)
6.4 days (SD 4.6, n
= 20)
7.6 days (SD 5.6, n
= 20)
No difference MD -1.20 (95% CI
-4.38 to 1.98)
Nasal mucosity du-
ration (delayed pre-
scription at time of
visit)
15.2 days (SD9.7, n
= 29)
13.0 days (SD 8.8, n
= 20)
No difference MD 2.20 (95%CI -
3.03 to 7.43)
Nasal mucosity du-
ration (delayed pre-
scription requiring
collection)
10.7 days (SD7.2, n
= 20)
13.0 days (SD 8.8, n
= 20)
No difference MD -2.30 (95% CI
-7.28 to 2.68)
CI: confidence interval
MD: mean difference
OR: odds ratio
SD: standard deviation
SMD: standardised mean difference
Table 3. Summary of clinical outcomes: delayed versus no antibiotics
Study Outcome Delay No antibiotics Favours Result (with 95%
CI)
Sore throat
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Table 3. Summary of clinical outcomes: delayed versus no antibiotics (Continued)
De la Poza Abad
2016
Pain duration (de-
layed prescription at
time of visit)
5.7 days (SD 5.1, n
= 45)
7.8 days (SD 6.0, n
= 46)
No difference MD -2.10 (95% CI
-4.39 to 0.19)
Pain duration (de-
layed
prescription requir-
ing collection)
7.4 days (SD 6.3, n
= 46)
7.8 days (SD 6.0, n
= 46)
No difference MD -0.40 (95% CI
-2.91 to 2.11)
Fever duration (de-
layed prescription at
time of visit)
3.1 days (SD 1.8, n
= 45)
3.2 days (SD 2.5, n
= 46)
No difference MD 0.10 (95% CI
0.99 to 0.79)
Fever duration (de-
layed
prescription requir-
ing collection)
3.4 days (SD 2.4, n
= 46)
3.2 days (SD 2.5, n
= 46)
No difference MD 0.20 (95% CI -
0.80 to 1.20)
Cough du-
ration (delayed pre-
scription at time of
visit)
8.1 days (SD 5.9, n
= 45)
10.6 days (SD 8.6, n
= 46)
No difference MD 0.0 (95%CI -2.
37 to 2.37)
Cough du-
ration (delayed pre-
scription requiring
collection)
8.2 days (SD 6.9, n
= 46)
10.6 days (SD 8.6, n
= 46)
No difference MD 0.10 (95% CI -
2.48 to 2.68)
Nasal mucosity du-
ration (delayed pre-
scription at time of
visit)
7.2 days (SD 4.3, n
= 45)
8.9 days (SD 6.5, n
= 45)
No difference MD -1.70 (95% CI
-3.96 to 0.56)
Nasal mucosity du-
ration (delayed pre-
scription requiring
collection)
9.7 days (SD 8.3, n
= 46)
8.9 days (SD 6.5, n
= 46)
No difference MD 0.80 (95% CI -
2.25 to 3.85)
Little 2005a Clinical outcomes Unavailable Unavailable No difference Unavailable
Acute otitis media
Chao 2008 Fever day 3 18/106 8/100 No difference OR 1.45 (95% CI 0.
50 to 4.24)
Pain day 3 26/106 29/100 No difference OR 0.64 (95% CI 0.
29 to 1.38)
Cough
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Table 3. Summary of clinical outcomes: delayed versus no antibiotics (Continued)
De la Poza Abad
2016
Pain duration (de-
layed prescription at
time of visit versus
no antibiotics)
11 days (SD 8.0, n =
32)
12.2 days (SD 8.0, n
= 32)
No difference MD -1.20 (95% CI
-5.07 to 2.67)
Pain duration (de-
layed
prescription requir-
ing collection versus
no antibiotics)
8.9 days (SD 6.9, n
= 32)
12.2 days (SD 7.8, n
= 32)
No difference MD -3.30 (95% CI
-6.91 to 0.31)
Fever duration (de-
layed prescription at
time of visit versus
no antibiotics)
5.6 days (SD 5.9, n
= 32
7.2 days (SD 7.9, n
= 32)
No difference MD -1.60 (95% CI
-8.82 to 5.62)
Fever duration (de-
layed
prescription requir-
ing collection versus
no antibiotics)
4.7 days (SD 4.6, n
= 32)
7.2 days (SD 7.9, n
= 32)
No difference MD -2.50 (95% CI
-5.67 to 0.67)
Cough du-
ration (delayed pre-
scription at time of
visit versus no an-
tibiotics)
15.6 days (SD8.8, n
= 32)
15.1 days (SD 7.6, n
= 32)
No difference MD -0.50 (95% CI
-3.53 to 4.53)
Cough du-
ration (delayed pre-
scription requiring
collection versus no
antibiotics)
12.0 days (SD5.6, n
= 32)
15.1 days (SD 7.6, n
= 32)
No difference MD -3.10 (95% CI
-6.37 to 0.17)
Common cold
De la Poza Abad
2016
Pain duration (de-
layed prescription at
time of visit versus
no antibiotics)
8.4 days (SD 8.2, n
= 29)
13.7 days (SD 6.7, n
= 19)
Delayed antibiotics MD -5.30 (95% CI
-9.54 to -1.06)
Pain duration (de-
layed
prescription requir-
ing collection versus
no antibiotics)
10.1 days (SD7.5, n
= 20)
13.7 days (SD 6.7, n
= 19)
No difference MD -3.60 (95% CI
-8.06 to 0.86)
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Table 3. Summary of clinical outcomes: delayed versus no antibiotics (Continued)
Fever duration (de-
layed prescription at
time of visit versus
no antibiotics)
3.0 days (SD 1.2, n
= 29)
9.0 days (SD 8.9, n
= 19)
Delayed antibiotics MD -6.00 (95% CI
-10.03 to -1.97)
Fever duration (de-
layed
prescription requir-
ing collection versus
no antibiotics)
4.2 days (SD 3, n =
20)
9.0 days (SD 8.9, n
= 19)
Delayed antibiotics MD -4.80 (95% CI
-9.01 to -0.59)
Cough du-
ration (delayed pre-
scription at time of
visit versus no an-
tibiotics)
8.3 days (SD 5.2, n
= 29)
11.7 days (SD 6.4, n
= 19)
No difference MD -3.40 (95% CI
-6.84 to 0.04)
Cough du-
ration (delayed pre-
scription requiring
collection versus no
antibiotics)
6.4 days (SD 4.6, n
= 20)
11.7 days (SD 6.4, n
= 19)
Delayed antibiotics MD -5.30 (95% CI
-8.81 to -1.79)
Nasal mucosity du-
ration (delayed pre-
scription at time of
visit versus no an-
tibiotics)
15.2 days (SD9.7, n
= 29)
15.2 days (SD 7.5, n
= 19)
No difference MD -0.0 (95% CI -
4.88 to 4.88)
Nasal mucosity (de-
layed
prescription requir-
ing collection versus
no antibiotics)
10.7 days (SD7.2, n
= 20)
15.2 days (SD 7.5, n
= 19)
No difference MD -4.50 (95% CI
-9.12 to 0.12)
CI: confidence interval
MD: mean difference
OR: odds ratio
SD: standard deviation
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A P P E N D I C E S
Appendix 1. Living systematic review protocol
Themethods outlined below are specific to maintaining the review as a living systematic review on the Cochrane Library (Synnot 2017).
They will be implemented immediately upon publication of this update. Core review methods, such as the criteria for considering
studies in the review and assessment of risk of bias, are unchanged. As such, we outline below only those areas of the methods for which
additional or different activities are planned or rules apply.
Search methods for identification of studies
These database searches are now being re-run using auto-alerts to deliver the monthly yield search by email. We will review search
methods and strategies approximately yearly, to ensure that they reflect any terminology changes in the topic area, or in the databases.
Searching other resources
As additional steps to inform the living systematic review, we will contact corresponding authors of ongoing studies as they are identified,
and ask them to share early or unpublished data. We will also contact the corresponding authors of any newly included studies for
advice as to other relevant studies. We will conduct citation tracking of included studies in Web of Science Core Collection on an
ongoing basis, using citation alerts in Web of Science Core Collection.
Selection of studies
For the monthly searches, we will immediately screen any new citations retrieved.
Data synthesis
When new evidence (studies, data or information) that meets the review inclusion criteria is identified, we will immediately assess risk
of bias and extract the data and incorporate it in the synthesis, as appropriate. We will not adjust the meta-analyses to account for
multiple testing given that the methods related to frequent updating of meta-analyses are under development (Simmonds in press).
Differences between protocol and review
This update includes some new methods relevant to living systematic reviews, which are included in the Methods section.
Appendix 2. Cochrane’s living systematic review pilot
Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant
new evidence as it becomes available (Elliott 2014; Synnot 2017). Cochrane is exploring the feasibility of preparing and publishing
living systematic reviews in a series of pilots (of which this review is one). For the Cochrane pilots, searching is being conducted monthly,
and new relevant evidence (studies, data or other information) will be incorporated into the review in a timely manner, so that the
findings of the review remain current.
For the most up-to-date information about the review, the results of the searches, and any new evidence being incorporated, readers
are encouraged to check the update status information. The update status information will be updated whenever the searches are re-
run. The review will be updated with a new citation whenever a new trial, or relevant information about already included trials (e.g.
new outcome data), is found.
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Appendix 3. CENTRAL, MEDLINE, Embase, CINAHL, and Web of Science search strategies (May
2017)
Cochrane Central Register of Controlled Trials (CENTRAL)
#1 MeSH descriptor: [Respiratory Tract Infections] explode all trees 11364
#2 ((upper next respiratory next tract next infection*) or URTI):ti,ab,kw 3288
#3 MeSH descriptor: [Otitis Media] explode all trees 1142
#4 (otitis next media):ti,ab,kw 2330
#5 MeSH descriptor: [Pharyngitis] explode all trees 1044
#6 pharyngitis:ti,ab,kw 1936
#7 MeSH descriptor: [Tonsillitis] explode all trees 379
#8 tonsillitis:ti,ab,kw 841
#9 MeSH descriptor: [Common Cold] explode all trees 427
#10 (common next cold*):ti,ab,kw 1011
#11 MeSH descriptor: [Bronchitis] explode all trees 1552
#12 bronchitis:ti,ab,kw 3462
#13 MeSH descriptor: [Sinusitis] explode all trees 880
#14 sinusitis:ti,ab,kw 2268
#15 (sore next throat*):ti,ab,kw 1761
#16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 21200
#17 MeSH descriptor: [Anti-Bacterial Agents] explode all trees 10749
#18 antibiotic*:ti,ab,kw 21099
#19 #17 or #18 26699
#20 (delay* near/15 prescri*):ti,ab,kw 117
#21 #16 and #19 and #20 34
Ovid MEDLINE
1 exp Respiratory Tract Infections/ (333159)
2 (upper respiratory tract infection$ or urti).mp. (5051)
3 exp Otitis Media/ (24227)
4 otitis media.mp. (28308)
5 exp Pharyngitis/ (14945)
6 pharyngitis.mp. (9818)
7 exp Tonsillitis/ (7710)
8 tonsillitis.mp. (8717)
9 exp Common Cold/ (4111)
10 common cold.mp. (5606)
11 exp Bronchitis/ (28759)
12 bronchitis.mp. (31223)
13 exp Sinusitis/ (19143)
14 sinusitis.mp. (24467)
15 sore throat$.mp. (4552)
16 or/1-15 (381421)
17 exp Anti-Bacterial Agents/ (642079)
18 antibiotic$.mp. (317830)
19 or/17-18 (782421)
20 (delay$ adj15 prescri$).mp. (947)
21 16 and 19 and 20 (100)
22 (2013* or 2014* or 2015* or 2016* or 2017*).ed. (4463544)
23 21 and 22 (37)
Ovid Embase
1 exp Respiratory Tract Infection/ (386692)
2 exp Upper Respiratory Tract Infection/ (42709)
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3 (upper respiratory tract infection$ or urti).mp. (26164)
4 exp Otitis Media/ (35233)
5 otitis media.mp. (38904)
6 exp Pharyngitis/ (27035)
7 pharyngitis.mp. (18176)
8 exp Tonsillitis/ (14789)
9 tonsillitis.mp. (14114)
10 exp Common Cold/ (8474)
11 common cold.mp. (10180)
12 exp Bronchitis/ (63141)
13 bronchitis.mp. (53196)
14 exp Sinusitis/ (39583)
15 sinusitis.mp. (37060)
16 sore throat$.mp. (15576)
17 or/1-16 (536945)
18 exp antibiotic agent/ (1228358)
19 antibiotic$.mp. (674521)
20 or/18-19 (1398274)
21 (delay$ adj15 prescri$).mp. (1402)
22 17 and 20 and 21 (144)
23 (2013* or 2014* or 2015* or 2016* or 2017*).em. (31737001)
24 22 and 23 (136)
EBSCO CINAHL Plus
S15 S10 and S13 and S14
S14 TI delay* N15 prescri* or AB delay* N15 prescri*
S13 S11 or S12
S12 TI antibiotic* or AB antibiotic*
S11 (MH “Antibiotics+”)
S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9
S9 TI (otitis media or pharyngitis or tonsillitis or common cold* or bronchitis or sinusitis or sore throat*) or AB (otitis media or
pharyngitis or tonsillitis or common cold* or bronchitis or sinusitis or sore throat*)
S8 (MH “Sinusitis+”)
S7 (MH “Bronchitis+”)
S6 (MH “Common Cold”)
S5 (MH “Tonsillitis+”)
S4 (MH “Pharyngitis”)
S3 (MH “Otitis Media+”)
S2 TI ( upper respiratory tract infection* or urti ) or AB ( upper respiratory tract infection* or urti )
S1 (MH “Respiratory Tract Infections+”)
Web of Science
#15#14 AND #11 AND #10
#14#13 OR #12
#13TS=prescri*
#12TS=delay*
#11TS=antibiotic*
#10#9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#9TS=“sore throat*”
#8TS=sinusitis
#7TS=bronchitis
#6TS=“common cold”
#5TS=tonsillitis
#4TS=pharyngitis
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#3TS=“otitis media”
#2TS=urti
#1TS=“Respiratory Tract Infection*”
F E E D B A C K
Feedback: Analysis 15.01 Comparison 15 may have some errors, 9 June 2008
Summary
Feedback: Analysis 15.01 Comparison 15 Patient satisfaction immediate versus delayed antibiotics, Outcome 01 Patient satisfaction:
immediate versus delayed antibiotics may have some errors.
We think that the extracted data has been entered under the wrong headings, i.e. for Little 1997, it reports that 165/177 were satisfied
with delayed antibiotics but the RevMan forest plot has 165/177 under the immediate antibiotics.
Data extracted from one article (Dowell 2001) may have been entered incorrectly, i.e. the percentage has been entered into RevMan
directly rather than as the actual number. In other words, for Dowell 2001, the paper reports 100% (73% very satisfied and 27%
moderately satisfied), whereas the forest plot has reported the 73% as 73/75. This is a double query ? see below for issue of inconsistent
grouping of satisfaction scores.
Suggest that the data extracted for Dowell 2001 should be consistent with the logic used for Arroll 2002 in their results for the same
outcome. We think that possibly the forest plot analysis should be conducted with the figures below. We have looked at all the original
papers.
Arroll 2002a
64/67* delayed Antibiotics
58/62* Immediate Antibiotics
Dowell 2001
71/73# delayed Antibiotics
75/75# Immediate Antibiotics
Little 1997
165/177 delayed Antibiotics
202/211 Immediate Antibiotics
Little 2001
115/150 delayed Antibiotics
123/135 Immediate Antibiotics
Little 2005a
147/190 delayed Antibiotics
166/194 Immediate Antibiotics
Arroll et al noted that for these results, groups responding 1 and 2 have been combined and groups 3 and 4 have been combined
where: 1= very satisfied; 2= moderately satisfied; 3 = slightly satisfied; 4 = not at all satisfied.
Using similar logic as Arroll et al, results for groups responding ?very satisfied? and ?moderately satisfied? have been combined, as have
?not very satisfied? and ?not at all satisfied? to get the figures in the table above for Dowell 2001. (Note: in the review table, the figures
were extracted directly from the ?very satisfied? column only, where they were presented as a percentage without then recalculating
them as a whole figure).
We don’t think these possible errors effect the overall conclusions made by the authors in the review.
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Submitter agrees with default conflict of interest statement:
I certify that I have no affiliations with or involvement in any organisation or entity with a financial interest in the subject matter of
my feedback.
Reply
We thank those who have given feedback on this review. We greatly appreciate the work you have done to uncover these errors and
the opportunity you have given us to correct them. We agree with all the feedback you have submitted and have made corrections
to analysis 15 comparison 15.1, analysis 16 comparison 16.1, analysis 13 comparison 13.1 (antibiotic use delayed versus immediate),
analysis 14 comparison 14.1 (antibiotic use delayed versus none) and analysis 3 comparison 3.1 (fever severity on day 3). We have also
added an analysis 17: adverse events delayed versus no antibiotics.
These changes have not fundamentally changed the results of the review. However the text and outcome tables have been amended to
reflect changes made.
Geoff Spurling, Chris Del Mar, Liz Dooley
Feedback reply added 25 June 2008
Contributors
Dianne Lowe, Rebecca Ryan
Feedback comment added 16 June 2008
It would be interesting to explore the comparative evidence base for the most effective method of
delayed prescription, 18 March 2009
Summary
Feedback: It would be interesting to explore the comparative evidence base for the most effective method of “delayed prescription” e.g.:
1. Script dated today given to patient
2. Script dated 2-3 days from now - given to patient
3. Script held at practice
Submitter agrees with default conflict of interest statement:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Reply
We thank you for your feedback on this review. We agree that it would be interesting to explore the comparative evidence base for
the most effective method of delayed prescription. Subgroups highlighting the method of delayed prescribing have been added for the
outcomes antibiotic use and patient satisfaction. Unfortunately, there was great heterogeneity in the methods of delayed prescribing that
makes combining studies difficult. Methods of delayed prescribing ranged from issuing a prescription at the time of the initial consults
with instruction to delay, to holding the delayed prescription at reception to be picked up if symptoms hadn’t improved after a specified
period of time. The recommended periods of delay ranged from three to fourteen days.
The three studies included in this systematic review published prior to 1992 examined the concern that immediate antibiotics for
streptococcal pharyngitis might impair the body’s immune response and predispose the patient to a relapse of pharyngitis. Six of the
included studies published after 1992 were conducted to evaluate the role of delayed antibiotics as a way of reducing antibiotic use for
respiratory infections compared to immediate antibiotics. While all six studies found that antibiotic use was significantly reduced in
the delayed antibiotic group compared to the immediate antibiotic group. There were significant differences in the way antibiotics were
delayed which may have contributed to the marked heterogeneity of this result. Of the seven studies published after 1991, four had the
delayed script kept at reception to be picked up (Dowell 2001; Little 1997; Little 2001; Little 2005a) and in three, the script was issued
to patients with instructions to delay (Arroll 2002a; Chao 2008; Spiro 2006). For the delayed arms of the four studies where the script
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was left at reception, antibiotics were used in 28% of cases (173/618) compared with antibiotics being used in 40% of cases (122/305)
where antibiotics were issued to patients with instructions to delay.
None of the included studies specifically addressed whether or not prescriptions had been post-dated. However, a randomised controlled
trial published in 2010, (Worrall 2010) comparing delayed prescriptions dated either the day of the office visit or 2 days later, but
not comparing with either immediate or no antibiotics, demonstrated no significant difference between the two groups in terms of
antibiotic use.
Geoff Spurling, Chris Del Mar, Liz Dooley, Rebecca Farley
Feedback reply added 25 March 2012
AnRCT published in 2016 explored the comparative evidence base for four differentmethods of delayed prescribing. The trial compared
patients randomised to either re-contact for a prescription, post-dated prescription, collection of the prescription or patient led (the
patient was given the prescription. This study did not compare delayed versus immediate or no antibiotics and consequently did not
meet the inclusion criteria for this review.
Contributors
Jas Janjuha, Occupation Pharmacist
WH A T ’ S N E W
Date Event Description
12 September 2019 Amended This is a living systematic review. Searches are run and screened monthly. Last search date 11
September, 2019. Results of all new studies identified have been incorporated. The conclusions
of this Cochrane Review are therefore considered up to date
H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 4, 2004
Date Event Description
12 August 2019 Amended This is a living systematic review. Searches are run and
screened monthly. Last search date 12 August, 2019.
Results of all new studies identified have been incor-
porated. The conclusions of this Cochrane Review are
therefore considered up to date
25 May 2017 New search has been performed We updated the searches and included one new trial,
De la Poza Abad 2016, and excluded four new trials
(Agnew 2013; De la Poza Abad 2013; Little 2014;
Worrall 2010).
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(Continued)
25 May 2017 New citation required and conclusions have changed Patient satisfaction favoured delayed over no antibiotics
(odds ratio 1.49, 95% confidence interval 1.08 to 2.
06).
When doctors feel it is safe not to prescribe antibiotics
immediately, prescribing none with advice to return if
symptoms do not resolve, rather than delaying them,
will result in lower subsequent antibiotic use. However,
patient satisfaction may be greater when a delayed pre-
scribing strategy is used; this will still result in a signifi-
cant reduction in antibiotic use compared to an imme-
diate prescribing strategy. No antibiotics resulted in the
least antibiotic prescribing.
28 February 2013 New search has been performed We have updated the searches. We included two
newpapers (Little 2006;Moore 2009), which reported
longer-term outcomes of two previously included stud-
ies (Little 2001; Little 2005a), including impact of de-
layed antibiotic prescribing on earache recurrence and
subsequent consultation rates in the 12 months follow-
ing the initial consultation. We excluded three new tri-
als (Fischer 2009; Newson 2009; Vouloumanou 2009)
. Our conclusions remain unchanged.
28 February 2013 New citation required but conclusions have not
changed
A new author joined the team to update the review.
5 August 2010 Amended Contact details updated.
27 March 2009 New search has been performed Searches conducted. This 2009 update contains one
new study, Chao 2008, and Feedback on a comment
submitted via the Cochrane Library
16 June 2008 Amended Converted to new review format.
16 June 2008 Feedback has been incorporated Feedback comment added.
21 January 2007 New search has been performed Searches conducted.
9 January 2004 New search has been performed Searches conducted.
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C O N T R I B U T I O N S O F A U T H O R S
• Chris Del Mar (CDM) conceived the review.
• Geoffrey Spurling (GS) and CDM designed the review.
• Ruth Foxlee (RFo) and GS performed the literature searches.
• RFo, Liz Dooley (LD), and CDM appraised articles and extracted data.
• GS and Rebecca Farley entered data into Review Manager 5 with contributions from LD, RFo, and CDM.
• GS secured funding for the review with the assistance of CDM.
D E C L A R A T I O N S O F I N T E R E S T
Geoffrey KP Spurling: None known.
Chris B Del Mar: None known.
Liz Dooley: None known.
Ruth Foxlee: I am an employee of the Cochrane Editorial Unit (a centrally funded Cochrane unit). My employment did not impact
in any way on my writing of this review, but I have disclosed these details for completeness.
Rebecca Farley: None known.
S O U R C E S O F S U P P O R T
Internal sources
• Bond University, Gold Coast, Australia.
• The Discipline of General Practice at the University of Queensland, Australia.
For providing the infrastructure that allowed the first publication of this review to be conducted.
External sources
• General Practice Education and Training, Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this 2017 update we expanded the Objectives to include the remaining primary outcomes, that is antibiotic use, patient satisfaction,
and antibiotic resistance, as these outcomes are very important for clinicians.
This update includes summary of findings tables which were not specified in the protocol.
This update includes some newmethods relevant for living systematic reviews, which are included in theMethods and are also described
in Appendix 1.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Drug Prescriptions; Acute Disease; Anti-Bacterial Agents [∗administration & dosage]; Common Cold [drug therapy]; Cough [drug
therapy]; Drug Administration Schedule; Fever [∗drug therapy; etiology]; Otitis Media [drug therapy]; Pain [drug therapy]; Patient
Satisfaction; Pharyngitis [drug therapy]; Randomized Controlled Trials as Topic; Respiratory Tract Infections [complications; ∗drug
therapy]; Time Factors
MeSH check words
Adult; Child; Humans
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